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Pathologic tau modifications are characteristic of Alzheimer’s disease and related dementias, but mechanisms of tau toxicity continue
to be debated. Inherited mutations in tau cause early onset frontotemporal lobar dementias (FTLD-tau) and are commonly used to
model mechanisms of tau toxicity in tauopathies. Previous work in the isolated squid axoplasm model demonstrated that several path-
ogenic forms of tau inhibit axonal transport through a mechanism involving activation of protein phosphatase 1 (PP1). Here, we
determined that P301L and R5L FTLD mutant tau proteins elicit a toxic effect on axonal transport as monomeric proteins. We eval-
uated interactions of wild-type or mutant tau with specific PP1 isoforms (a, b, and c) to examine how the interaction contributes to
this toxic effect using primary rat hippocampal neurons from both sexes. Pull-down and bioluminescence resonance energy transfer
experiments revealed selective interactions of wild-type tau with PP1a and PP1c isoforms, but not PP1b, which were significantly
increased by the P301L tau mutation. The results from proximity ligation assays confirmed the interaction in primary hippocampal
neurons. Moreover, expression of FTLD-linked mutant tau in these neurons enhanced levels of active PP1, also increasing the pausing
frequency of fluorescently labeled vesicles in both anterograde and retrograde directions. Knockdown of PP1c, but not PP1a, rescued
the cargo-pausing effects of P301L and R5L tau, a result replicated by deleting a phosphatase-activating domain in the amino termi-
nus of P301L tau. These findings support a model of tau toxicity involving aberrant activation of a specific PP1c-dependent pathway
that disrupts axonal transport in neurons.
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Significance Statement
Tau pathology is closely associated with neurodegeneration in Alzheimer’s disease and other tauopathies, but the toxic mechanisms
remain a debated topic. We previously proposed that pathologic tau forms induce dysfunction and degeneration through aberrant
activation of a PP1-dependent pathway that disrupts axonal transport. Here, we show that tau directly interacts with specific PP1
isoforms, increasing levels of active PP1. Pathogenic tau mutations enhance this interaction, further increasing active PP1 levels and
impairing axonal transport in isolated squid axoplasm and primary hippocampal neurons. Mutant-tau-mediated impairment of
axonal transport was mediated by PP1g and a phosphatase-activating domain located at the amino terminus of tau. This work has
important implications for understanding and potentially mitigating tau-mediated neurotoxicity in tauopathies.
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Introduction
The microtubule-binding protein tau is a major component of the
axonal cytoskeleton, and its normal physiological role remains a
matter of debate (Guo et al., 2017). Pathologic tau modifications,
including phosphorylation of specific residues and formation of
multimers, are closely associated with Alzheimer’s disease (AD)
and related tauopathies. These modifications are typically linked
to tau conformation changes that spatially and temporally corre-
late with dysfunction and dying-back degeneration of neurons
within affected brain regions across different tauopathies (Kovacs,
2015; Kneynsberg et al., 2017). Most tauopathies are sporadic, but
a number of inherited mutations within the MAPT (microtubule-
associated protein tau) gene encoding tau induce early onset neu-
rodegeneration classified within frontotemporal lobar dementias
(FTLD-tau; Hutton et al., 1998; Ghetti et al., 2015; Forrest et al.,
2018). Specific single-point mutations (e.g., the P301L and R5L
mutations) can induce disease in humans and promote neurologic
phenotypes in animal models of tauopathies (Lewis et al., 2000;
Poorkaj et al., 2002; Tatebayashi et al., 2002; Santacruz et al.,
2005).
Mutations alter conformation, phosphorylation state, micro-
tubule binding, isoform composition, and/or aggregation pro-
pensity of tau protein in tauopathies (Ghetti et al., 2015). Any of
these modifications could enhance tau toxicity in disease, but
many questions remain about the underlying molecular mecha-
nisms. Similarly, questions on whether pathologic modifications
alter normal functions of tau, generate new biological activities, or
both remain open. Much of the focus on the cellular functions of
tau has centered on its affinity for microtubules and ability to pro-
mote microtubule assembly or stabilization in vitro (Weingarten
et al., 1975). However, recent work identified functional roles of
tau unrelated to regulation of microtubule dynamics. Notably, tau
plays a role in signal transduction by regulating the localization
and enzymatic activity of kinases and phosphatases involved in a
diverse set of cellular processes (Lee et al., 1998; Liao et al., 1998;
Ittner et al., 2010; Kanaan et al., 2013; Mueller et al., 2021).
Fast axonal transport (FAT), a complex set of microtubule-
based intracellular trafficking events involving bidirectional
movement of organelles along axons, is one cellular process
affected by pathogenic tau. Using squid axoplasm preparations, a
well-established experimental model to study FAT, we showed
that physiological, or even supraphysiological, levels of normal
human tau monomers did not negatively affect FAT (Morfini et
al., 2007). In contrast, conformation-changing pathologic tau
alterations, (aggregation/oligomerization or specific modifications
to monomers), impaired FAT at physiological levels in this model
(LaPointe et al., 2009; Kanaan et al., 2011; Patterson et al., 2011;
Cox et al., 2016; Tiernan et al., 2016). This toxic effect was medi-
ated through a protein phosphatase 1 (PP1)-dependent pathway
that resulted in cargo dissociation from the major microtubule-
based motor protein kinesin-1 and dependent on a biologically
active motif in the extreme amino terminus of tau termed the
phosphatase activating domain, (PAD; Morfini et al., 2004;
LaPointe et al., 2009; Kanaan et al., 2011). Collectively, these find-
ings indicated that pathologic tau modifications disrupt FAT by
altering tau conformation and dysregulating signaling pathways
through abnormal PP1 activation. Identification of putative PP1
binding sequences in tau suggested a direct interaction between it
and PP1, but this was not directly assessed.
In this study, we test the hypothesis that two FTLD-tau muta-
tions disrupt FAT via a PP1-dependent mechanism in mammalian
neurons. Using protein–protein interaction assays we found that
tau directly interacts with selected PP1 isoforms, and the disease-
causing P301L mutation enhances such interactions. Measuring a
regulatory phosphorylation site in PP1, we also show that tau
increases active PP1 levels, an effect enhanced by FTLD-tau muta-
tions. We demonstrate that both P301L and R5L mutant tau, but
not wild-type (WT) tau, impair FAT using isolated squid axo-
plasm and cultured neurons as complementary experimental sys-
tems. In mammalian neurons, the tau mutants impaired FAT by
increasing cargo pause frequency in a PP1g isoform-dependent
and PAD-dependent fashion. These findings establish a specific
molecular mechanism by which two disease-causing tau forms
similarly induce FAT impairments in mammalian neurons.
Materials and Methods
Recombinant protein purification. The tau constructs used here
included full-length human tau (i.e., the hT40 or 2N4R isoform) in both
WT- and FTLD-related P301L and R5L mutant forms (Hutton et al.,
1998; Poorkaj et al., 2002). All tau cDNAs were tagged with C-terminal
six-histidine (6xHis) tags and expressed in Escherichia coli using pT7C
backbones and IPTG induction, as previously described (Combs et al.,
2017). Briefly, recombinant proteins were separated using metal affinity
chromatography controlled by an ÄKTA pure fast protein liquid chro-
matography machine (Cytiva) on a HiTrap Talon Crude column
(Cytiva) followed by size-exclusion chromatography using a Hiprep 16/
60 Sephacryl S-500 HR column (Cytiva). The samples were then further
purified using a HiTrap Q HP anion-exchange column (Cytiva) using a
salt gradient from 0 to 250 mM NaCl. DTT was added to a final concen-
tration of 1 mM. All proteins were divided into single-use aliquots and
frozen at80°C. SDS-Lowry assays were used to determine protein con-
centrations (Combs et al., 2017).
Vesicle motility assays in squid axoplasm. Isolated axoplasm from
the squid Doryteuthis pealeii (Marine Biological Laboratory) was used to
measure the effects of tau monomers on FAT, as previously described
(Brady et al., 1993; LaPointe et al., 2009; Song et al., 2016). Monomeric
WT, P301L, or R5L tau protein stocks were diluted in X/2 buffer con-
taining the following (in mM): 175 potassium aspartate, 65 taurine, 35
betaine, 25 glycine, 10 HEPES, 6.5 MgCl2, 5 EGTA, 1.5 CaCl2, 0.5 glu-
cose, and 5 adenosine triphosphate, pH 7.2, to a final concentration of 2
mM and perfused into isolated axoplasm. Anterograde and retrograde
FAT rates were alternately obtained by matching the calibrated cursors
to the bulk flow of membrane-bounded organelles (e.g., synaptic
vesicles) for 50min after perfusion, as described previously (Song et al.,
2016). FAT rates over the last 20min of the assay were compared
between treatment groups as described previously (Cox et al., 2016;
Tiernan et al., 2016).
DNA cloning. DNA constructs were generated in a pCMV or pFIN
backbone. The HaloTag (Promega) was attached to the N-terminal end
of each of the PP1a, PP1b , and PP1g1 isoforms (PP1g exists as two
alternatively spliced isoforms, but PP1g1 is more prevalent in the brain
and is the specific isoform used whenever PP1g is referenced through-
out this article; Strack et al., 1999). The NanoLuciferase tag (Promega)
was attached to the C-terminal end of the WT, P301L, and R5L tau con-
structs. The P301L and R5L point mutations were generated using man-
ufacturer instructions for the QuikChange Lightning Site-Directed
Mutagenesis Kit (Agilent Technologies) in the pCMV vector and intro-
duced into the pFIN vector via restriction enzyme cloning techniques.
HaloTag-based pull-down assay. HEK293T cells (ATCC) were grown
at 37°C and 5% CO2 in the following cell culture media: DMEM1 L-glu-
tamine (Invitrogen), 5% FBS, 1% penicillin/streptomycin. Cells were not
used beyond passage 30.
Three hundred thousand HEK293T cells/well were plated into a 12-
well polystyrene plate. After 24 h, the cells were transfected with 500 ng
each of pCMV tau-NanoLuc (WT, P301L, or R5L) and pCMVHalo-PP1
(PP1a, PP1b , or PP1g ) or a pCMV Halo control (the HaloTag protein
only) using Lipofectamine 2000 and allowed to express proteins for 18 h
before collection. Immediately before cell lysis, 50ml of HaloLink resin
(25% slurry in 25% ethanol, Promega) was aliquoted for each sample.
The beads were washed 3 in 500ml of wash buffer (TBS, 0.05% NP-40,
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Sigma-Aldrich) with centrifugation steps of 800  g for 2min to settle
resin between each wash. Cells were lysed in 150ml of lysis buffer [50
mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, pepstatin (10mg/
ml), bestatin (10mg/ml), leupeptin (10mg/ml), phenylmethylsulfonyl flu-
oride (1 mM), aprotonin (10mg/ml)], then homogenized 20 with dis-
posable polypropylene dounce homogenization pestles (Sigma-Aldrich).
The samples were centrifuged at 14,000  g for 5min at 4°C, and the su-
pernatant was transferred to a new tube containing 350ml of TBS (50
mM Tris, 150 mM NaCl, pH 7.4). Next, 450ml of each sample lysate/TBS
mix was transferred to the HaloLink resin beads, and the remainder of
the lysates were frozen as preincubation lysate samples. The samples
were incubated for 1 h on a rotating mixer to allow covalent binding of
the HaloTagged PP1 or HaloTag-only as control. After incubation, sam-
ples were centrifuged at 800  g for 2min, and the supernatants were
saved as post-pull-down lysate samples. The beads were washed 4 in
800ml of wash buffer with the final wash step including a 5 min incuba-
tion on the rotating mixer. After removing the wash buffer, the beads
were incubated in 50ml of 2 sample buffer (40 mM Tris, pH 6.8, 4%
SDS, 12% glycerol, 2% b -mercaptoethanol, 0.004% bromophenol blue)
for 30min at 1000 rpm and 30°C in an Eppendorf ThermoMixer C.
After a centrifugation at 800  g for 2min, the supernatants were col-
lected as the pull-down sample.
For immunoblots, 12.5ml of preincubation and postincubation lysate
samples were added to 2.5ml of 6 sample buffer (final 1 composition
was 20 mM Tris, pH 6.8, 2% SDS, 6% glycerol, 1% b -mercaptoethanol,
0.002% bromophenol blue). These samples and the pull-down samples
(eluted in 2 sample buffer) were heated at 99°C for 5min. Fifteen microli-
ters of each of the lysate samples and 25ml of the pull-down samples were
separated using Criterion TGX Precast 4–20% gels (Bio-Rad) in SDS-
PAGE. The proteins were then transferred to BioTrace NT nitrocellulose
transfer membrane (Pall) at 400mA for 50min. The membranes were
blocked in 2%milk/TBS for 1 h at room temperature and then probed over-
night at 4°C with primary antibodies. All antibodies were diluted in 2%
milk/TBS. The R1 polyclonal rabbit antibody (10ng/ml; catalog #R1,
Nicholas M. Kanaan at Michigan State University; RRID:AB_2832929) was
used to detect tau (Berry et al., 2004). An anti-HaloTag mouse monoclonal
antibody (1mg/ml; catalog #G9211, Promega; RRID:AB_2688011) was used
to detect HaloTag proteins. Blots were rinsed with 0.1% Tween 20/TBS
(TBST) and then incubated with appropriate secondary antibodies diluted
1:20,000 in milk/TBS (IRDye 680RD goat anti-mouse IgG, catalog #926-
68070, Li-Cor Biosciences; RRID:AB_10956588; and IRDye 800CW goat
anti-rabbit IgG, catalog #926-32211, Li-Cor Biosciences; RRID:AB_621843).
The blots were imaged using a Li-Cor Odyssey infrared imaging system,
and Li-Cor ImageStudioLite 5.2 software was used to quantify immunoreac-
tivity of bands. The bulk of Halo-PP1 or Halo tag alone covalently binds to
the HaloLink resin and does not elute from the beads. Therefore, relative
tau levels in pull-down samples were calculated by normalizing tau signal
from the elution fraction to the change in Halo signal [tau elution signal/
(Halo pre-pulldown signal –Halo post-pull-down signal)].
Nano bioluminescence resonance energy transfer donor saturation
assay. The nano bioluminescence resonance energy transfer (nBRET) tech-
nique using a donor and acceptor tags was used to demonstrate protein–
protein interaction (Machleidt et al., 2015). The DNA constructs were
expressed in low-passage HEK293T cells through Lipofectamine2000
(Thermo Fisher Scientific) transfection in a 12-well polystyrene plate
(Corning). A donor saturation assay was used to demonstrate a specific
interaction between the two proteins and to indicate the relative strengths
of those interactions among the various tau and PP1 constructs. Each well
was transfected with 10ng of donor DNA (tau-NanoLuciferase) as well as
an amount of acceptor DNA (Halo-PP1 or HaloTag-only control) ranging
from 1000 to 1.4ng for final acceptor:donor DNA ratios of 100:1, 33.3:1,
11.1:1, 3.7:1, 1.2:1, 0.4:1, and 0.1:1. A control well that was transfected with
donor DNA (i.e., tau-luciferase) but no acceptor DNA (i.e., Halo-PP1 or
Halo only) was included. An empty nonexpressing pTRE3G plasmid
(Promega) was added to a final DNA concentration of ;1mg/transfection
to act as a carrier DNA and standardize the amount of total DNA being
transfected.
After 18 h, the cells were detached from the plate on addition of
500ml of 0.5% trypsin and a brief incubation at 37°C. After dissociation,
the trypsin was quenched with 1 ml of cell culture media. The cells were
centrifuged at 200  g for 2min and resuspended in 1 ml of OptiMEM
(no phenol red, 4% FBS, Invitrogen). Aliquots of each sample were
diluted in trypan blue (Bio-Rad) for cell counting. The cells were diluted
to a volume of 660ml at 200 cells/ml in OptiMEM (no phenol red, 4%
FBS). The cells were split into two samples. One received 0.33ml of 618
ligand (Promega), and the other received 0.33ml of DMSO as a control.
The 618 ligand attaches to the HaloTag and acts as the acceptor fluoro-
phore, whereas the DMSO control contains no fluorophore. Six wells of
each transfection condition were plated onto a 96-well, white-wall, clear-
bottom plate (three with 618 ligand and three with DMSO; Corning) at
20,000 cells and 100ml/well then incubated for 18–20 h. A 5 stock solu-
tion of Nano-Glo substrate (Promega) was prepared in OptiMEM (no
phenol red, 4% FBS). Twenty-fivemicroliters of the Nano-Glo substrate
stock was then added to each well and immediately placed in the BioTek
Synergy NEO HTS plate reader equipped with filtered luminescence
(BioTek). After shaking for 30 s, the luminescence values were read
using a 410/80 bandpass filter (donor signal) and 610 nm long-pass filter
(acceptor signal).
The mean corrected nBRET ratios were calculated according to the
provided manufacturer protocol. The raw milliBRET unit (mBU) ratio
was calculated by dividing the acceptor luminescence values by the do-
nor luminescence values and then multiplying by 1000. These values
were then corrected by subtracting the control milliBRET ratios (with
DMSO) from the experimental milliBRET ratios (with 618 ligand). The
mean and SD of these values were plotted versus the transfection DNA
ratios and fit to a hyperbolic curve using GraphPad Prism.
Primary neuron cultures. Timed-pregnant Sprague Dawley rats
(Harlan Laboratories) were used to obtain embryonic d 18 (E18) fetuses
(both sexes) for culturing primary hippocampal neurons, as previously
described (Grabinski et al., 2015). Rats were housed in a room with a 12
h light/dark cycle and provided food and water ad libitum. Procedures
were conducted in compliance with federal, state, and institutional
guidelines and approved by the Michigan State University Institutional
Animal Care and Use Committee.
Briefly, hippocampi were dissected from the rat embryos, cut
into small pieces, and placed in ice-cold calcium- and magnesium-
free buffer [CMF; Dulbecco’s PBS (Invitrogen) with 0.1% glucose
(Sigma-Aldrich), 2.5mg/ml fungizone (Invitrogen), and 50 mg/ml
gentamicin (Invitrogen)]. The tissue was washed 4 with CMF
and incubated in 0.125% trypsin for 15 min at 37°C and washed
again 2 with CMF then suspended in trypsin-inactivation solu-
tion (HBSS, Invitrogen), 50mg/ml DNase I (Worthington), and
20% newborn calf serum (Invitrogen). Cells were dissociated through tritu-
ration using progressively smaller diameter syringes, pelleted over FBS
(200  g at 4°C) and then resuspended and plated in antibiotic-free neuro-
basal media (Invitrogen) supplemented with 1% GlutaMAX (Invitrogen)
and 2% B-27 (Invitrogen).
Lentivirus production. Lentiviral stocks were prepared to individually
express WT tau, P301L tau, R5L tau, and GFP in primary neuron cul-
tures. DNA constructs including a pHEF VSV-G envelope vector, a
pNHP packaging vector (Coleman et al., 2003), and a pFIN construct to
express the various versions of C-terminally FLAG-tagged tau under
control of the chicken beta-actin promoter were cotransfected into four
150 mm culture dishes containing Hek293T cells at ;50–60% conflu-
ency. A full cell culture media change was performed 2 h before transfec-
tion. The DNA was combined with 22.5mg of pFIN tau, 15mg of pNHP,
and 7.5 mg of pHEF VSV-G DNA/plate, and then added to 2.4 ml of
0.1 TE (10 mM Tris, 1 mM EDTA, pH 8.0) and 1.2 ml sterile deionized
water. Then 400ml of 2.5 M CaCl2 was mixed into the solution and incu-
bated for 5min at RT followed by a dropwise addition of 4 ml of 2
HBS containing the following (in mM): 281 NaCl, 100 HEPES, and 1.5
Na2HPO4, pH 7.12, into the gently vortexed solution. The transfection
solution was then evenly distributed throughout the plates at 2 ml/dish
and incubated overnight. The media was then changed to viral cell cul-
ture media (DMEM, 2% FBS, 1% penicillin/streptomycin). The superna-
tants were collected on days 3 and 4 post-transfection by centrifuging at
675  g for 5min, then filtering through 0.45mm filters. A 2 ml 20% su-
crose bed was laid below the clarified media in ultracentrifuge tubes then
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spun in a swinging bucket rotor at 82,700  g for 2 h at 4°C. The super-
natant was removed, and the pellet was resuspended in 500ml of PBS
then aliquoted and frozen at 80°C after the second collection.
Lentiviral titers were determined using a Lenti X P24 Rapid Titration
Elisa Kit (TaKaRa Bio) according to manufacturer protocol, and similar
levels of tau expression were confirmed via immunoblotting before use.
Proximity ligation assay. Primary rat hippocampal neuron cultures
were prepared as described above. Forty thousand cells were plated into
each well of an eight-well chamber slide (Ibidi) coated with poly-D-ly-
sine, and the cultures were treated with lentivirus at 0.25pg of p24 pro-
tein/plated cell on day in vitro (DIV) 4 to express WT tau, P301L tau, or
R5L tau. Additional control wells were left untreated with virus. After
4 d of incubation the cells were fixed with a 20min treatment of 4% para-
formaldehyde in cytoskeleton buffer containing the following (in mM):
10 MES, 138 KCl, 3 MgCl2, and 4 EGTA, pH 6.1, followed by three 5
min washes in TBS. The cells were permeabilized and incubated in
blocking buffer (5% goat serum, 1% BSA, and 0.2% Triton X-100 in
TBS) for 1 h at room temperature. Neurons expressing each tau con-
struct and the untreated cells were then incubated with Tau7 antibody
(catalog #Tau7, Nicholas M. Kanaan at Michigan State University;
RRID:AB_2721195; Horowitz et al., 2006) at 2.5 ng/ml and a PP1 anti-
body (catalog #PA5-28218, Thermo Fisher Scientific; RRID:AB_
2545694) or a PP1g -specific antibody (catalog #07-1218, Millipore;
RRID:AB_1977432) at 1:500 dilutions in 2% goat serum/TBS overnight
at 4°C. Neurons expressing WT tau and untreated cells were incubated
with each antibody individually or no primary antibodies for proximity
ligation assays (PLAs) method controls. The Duolink PLA Control Kit
(Sigma-Aldrich) was used to identify an association between tau and
PP1 in the neurons. The cells were washed 3 5min at room tempera-
ture Buffer A then incubated with anti-mouse PLUS and anti-rabbit
MINUS secondary probes (1:5 dilution each) in 2% goat serum for 1 h at
37°C. After 3 additional 5min washes in buffer A, the neurons were
incubated in ligase (1:40 dilution) in 1 ligation buffer for 30min at 37°
C and washed 3 in Buffer A again. Next, the neurons were incubated
with polymerase (1:80 dilution) in 1 amplification buffer for 100min
at 37°C followed by incubation in blocking buffer for 1 h at room tem-
perature. Then cells were incubated overnight at 4°C with biotinylated
Tau12 antibody (catalog #Tau12, Nicholas M. Kanaan at Michigan State
University; RRID:AB_2721192; Horowitz et al., 2006) at 2.5 ng/ml, and
Tuj1, a b -III tubulin antibody (catalog #TuJ1, A. Frankfurter,
University of Virginia, Department of Biology; RRID:AB_2315517;
Caccamo et al., 1989) at 100 ng/ml in 2% goat serum. Tau12 is a
human tau-specific antibody that does not label rodent tau and
was used to identify human tau-expressing neurons, whereas Tuj1
will label all neurons. The cells were washed 3 5min with TBS
then incubated with the following secondary antibodies:
Streptavidin-conjugated Alexa Fluor 568 conjugate antibody (cata-
log #S11226, Thermo Fisher Scientific; RRID:AB_2315774) at a
1:1000 dilution and Alexa Fluor goat-anti mouse IgG2a 647 anti-
body (1:500; catalog #A32728, Thermo Fisher Scientific; RRID:
AB_2633277) in 2% goat serum for 1 h at RT then washed again 3-
 5 min in TBS.
The cells were imaged on a Nikon A11 laser scanning confocal
microscope equipped with 488, 561, and 640 solid state lasers using a
60 1.40numerical aperture (NA) objective and Nikon Elements AR
software. We collected z-stack images over a depth of 2mm with 0.25mm
steps (nine images/stack). The displayed images represent maximum in-
tensity projections from the individual z-stack planes. Using a 40
1.3NA objective, we collected two to six images containing randomly
selected, isolated neurons expressing exogenous tau (Tau12-positive) for
each condition and replicate. Monochromatic images were produced for
each channel, and the data were quantified using FIJI ImageJ. For the
PLA puncta image (green channel) a threshold mask was generated
using the default threshold setting, and the number of puncta per image
was counted using the Count Particle function. The human tau signal
(red channel) was identified using post-PLA immunocytofluorescence
staining using the Tau12 antibody to label only exogenous tau as
described above. A thresholding mask was generated using the Huang
setting, and the total area of the mask was calculated using the Measure
function and converted from pixels to nm2. The number of puncta/total
area of Tau12 signal (nm2) was calculated for each image with a mini-
mum cutoff of five pixels. The individual data points (see Fig. 4C) repre-
sent the mean of the results from all analyzed images within an
individual replicate, and the experiment was repeated three independent
times.
Phospho-PP1 immunoblots. Low-passage HEK293T cells were
plated into a poly-D-lysine-coated 24-well plate at 200,000 cells/well
(experimental replications started with cells at the same initial pas-
sage number). After 24 h the cells were transfected with 0.5 mg of
DNA. Polyethylenimine (PEI) was incubated at 55°C for 5min
before 5 ml was added to 50 ml of 150 mM NaCl for each well; 0.5 mg
of DNA was also added to 50 ml of 150 mM NaCl. The PEI mix was
added to the DNA mix, vortexed briefly, and incubated at room
temperate for 20min. The samples were then added to the wells in a
dropwise manner. The lysates were collected in 75 ml of lysis buffer/
well (20 mM Tris, 0.5 mM DTT, 300 mM NaCl, 0.5% Triton X-100,
2mg/ml pepstatin, 2mg/ml bestatin, 2mg/ml leupeptin, 4 mM phen-
ylmethylsulfonyl fluoride, 10mg/ml aprotonin, 1 mM tetra-sodium
pyrophosphate decahydrate, 10 mM b -glycerophosphate, 1 mM so-
dium orthovanadate, 1 M sodium fluoride, pH 7.5), and two wells for
each condition were combined and sonicated with four pulses.
Lysate protein concentrations were determined using the Bio-Rad
protein assay as directed. Immunoblotting was performed as
described above by loading 40mg of total protein into 18-well gels
that were transferred to nitrocellulose.
Primary rat hippocampal neurons (E18) were plated at 600,000 cells/
well into six-well plates coated with poly-D-lysine as described above.
On DIV 4 the neurons were treated with lentivirus (0.5 pg p24/cell) to
induce expression of WT tau, P301L tau, R5L tau, or GFP. On DIV 8
lysates from individual wells were collected into 200ml of the same lysis
buffer described above and sonicated with four pulses. Cell lysate (55mg
of total protein) was loaded onto a 12-well gel for the PP1 blots and an
18-well gel (24mg of total protein) for the tau and GFP blots, then trans-
ferred to nitrocellulose. The primary neuron blots were blocked in 2%
milk-TBST for 1 h, washed 3 in TBST, then incubated with primary
antibodies in 5% BSA-TBST overnight at 4°C.
Blots were probed for phospho-PP1 (pT320; 1:500; catalog #2581,
Cell Signaling Technology; RRID:AB_330823), HaloTag (1:1000; catalog
#G9211, Promega; RRID: AB_2688011), Total PP1 (E-9; 1:400; catalog
#sc-7482, Santa Cruz Biotechnology; RRID:AB_628177), GAPDH (load-
ing control; 1:2000; catalog #5174, Cell Signaling Technology; RRID:
AB_10622025), Tau5 (10 ng/ml; catalog# Tau5, Nicholas M. Kanaan at
Michigan State University; RRID:AB_2721194; LoPresti et al., 1995;
Carmel et al., 1996), and GFP (1:30,000; catalog #ab290, Abcam; RRID:
AB_303395). Blots were detected with secondary antibodies and imaged
as described above. The pT320 PP1 (inactive form) signal was normal-
ized to total PP1 (HaloTag signal for the Hek293T blots and total PP1
signal for the neuron blots) to obtain relative changes in the levels of
active PP1. Notably, T320 in PP1a is analogous to T316 in PP1b and
T311 in PP1g . Tau signal was normalized to GAPDH signal to confirm
similar levels of protein expression and loading.
Live-cell FAT assay. Primary hippocampal neurons were prepared
as described earlier and plated at 80,000 cells/well into four-well live
cell chamber slides (Ibidi) coated with poly-D-lysine in 750ml of
neurobasal media (Invitrogen). The cells were transfected on DIV 8
using Lipofectamine 2000 reagent. A pFIN Synaptophysin-mApple
and a pCMV plasmid containing one of the genes of interest (WT
tau, P301L tau, R5L tau, D2–18 WT tau, D2–18 P301L tau, or GFP)
were coincubated at 200 ng each in 30 ml of Opti-MEM serum-free
media for 30min. For each well, 0.5 ml of Lipofectamine2000 was
also incubated in 30 ml of Opti-MEM media (Invitrogen) at room
temperature for 30min. The Lipofectamine mix was added to the
DNA mix and incubated for another 30min at room temperature.
Sixty microliters of sample was added throughout the entirety of
each well. After 2 h, half of the media (380 ml) was replaced with an
equivalent volume of neurobasal media containing an antibody that
binds the extracellular domain of neurofascin in the axon initial seg-
ment to differentiate the axon from dendrites during live cell
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imaging (250 ng/ml; catalog #75-172, Antibodies Incorporated;
RRID:AB_2282826) as described previously (Hedstrom et al., 2008).
At 24 h post-transfection, the media was replaced with neurobasal
media containing Alexa Fluor goat-anti-mouse IgG2a 647 antibody
(1mg/ml; catalog #A32728, Thermo Fisher Scientific; RRID:AB_
2633277).
After a 1 h incubation, the cells were imaged on the Nikon A11 laser
scanning confocal microscope using a 60 1.40NA objective and Nikon
Elements AR software. The plates were maintained in a live cell chamber at
37°C and 5% CO2 throughout the imaging process. Imaging of transports
was conducted in a main branch of the axon 50–150mm distal from the
axon initial segment. A region of 32 pixels by 128 pixels was bleached with
7 pulses of 1.7 s each from a 568nm laser at 60% power. After 2min a
movie was generated through imaging at ;28 frames per second (fps) for
5min using the 568nm laser to visualize movement of mApple-synapto-
physin cargo. Kymographs were generated using the ImageJ macro
KymoAnalyzer (Neumann et al., 2017). Tracks were drawn manually and
subsequently analyzed by the macro to generate data. Anterograde and ret-
rograde segment velocities represent a mean of each segment moving above
a threshold of 0.3mm/s. Each individual replicate in the primary neuron
experiments represents the mean value from all analyzed kymographs
within a given primary neuron preparation and represent completely inde-
pendent culture runs from different pregnant females. For each condition,
1–4 neurons were analyzed per preparation with a minimum cutoff of 30
detectable tracks per kymograph (GFP: n = 6 independent experiments, 15
total neurons; WT tau: n = 6 independent experiments, 14 total neurons;
P301L tau: n = 6 independent experiments, 15 total neurons; R5L: n = 5 in-
dependent experiments, 11 total neurons; see Fig. 7). All conditions
included five independent replicates (WT tau, 9 total neurons; D2–18 WT
tau, 8 neurons; P301L tau, 10 total neurons; D2–18 P301L tau, 9 neurons;
see Fig. 10).
PP1 shRNA validation. We generated shRNA sequence pairs to
achieve isoform-specific knockdown of PP1 as follows: PP1a: 59-GAT
CCGACGATACAACATCAAACTTTCAAGAGAAGTTTGATGTTGT
ATCGTCTTTTTTA-39 and 59-AGCTTAAAAAAGACGATACAACATC
AAACTTCTCTTGAAAGTTTGATGTTGTATCGTCG-39; PP1g : 59-GAT
CCGCGGATATCGATAAACTCAATTCAAGAGATTGAGTTTATCGAT
ATCCGTTTTTTA-39 and 59-AGCTTAAAAAACGGATATCGATAAAC
TCAATCTCTTGAATTGAGTTTATCGATATCCGCG-39; and a nontar-




Knockdown of PP1 was evaluated using a Dual-Luciferase Reporter
Assay System (Promega). HEK293T cells were plated into a poly-D-lysine-
coated 24-well plate at 150,000 cells/well and transfected the next day. The
transfection included 100ng of a fusion construct containing Renilla lucifer-
ase and a rat cDNA sequence for one of the three PP1 isoforms in a
psiCHECK-2 plasmid (also containing a separate firefly luciferase to control
for expression); 400ng of a pH1SH plasmid including shRNA sequences
for PP1a, PP1g , Renilla luciferase (positive control); a nontargeting control
sequence (negative control); or empty for normalization. Two days after
transfection, the cell culture media was replaced by 200ml of Passive Lysis
Buffer, and the cells were incubated on a shaker for 15min. Then 20ml of
lysate was transferred to white opaque 96-well plates in triplicate and placed
in a Promega GloMax-Multi Detection System. Following the Dual
Luciferase two-injector protocol, the instrument injected 100ml of
Luciferase Assay Reagent II and measured the firefly luciferase activity. It
then dispensed 100ml of Stop & Glo Reagent and measured the Renilla lu-
ciferase activity. The Renilla:Firefly luciferase activity signal ratios were nor-
malized to the average of the relevant Renilla fusion construct 1 empty
pH1SH vector and reported as percent of control. This indicates the per-
centage knockdown of PP1 expression for each of the PP1 and control
shRNA constructs.
We also confirmed mRNA knockdown in primary neurons using
droplet digital PCR (ddPCR). Primary rat hippocampal neurons were
plated at 150,000 cells/well into a 24-well plate and individually trans-
duced on DIV four with lentiviruses to express shRNA targeting PP1a,
PP1g , or a scrambled shRNA control. RNA was extracted using a
Qiagen RNeasy miniprep kit 8 d after transduction. The relative concen-
trations of PP1a and PP1g mRNA were quantified using ddPCR.
Onenanogram of extracted RNA from each sample was diluted into a
reaction mix as directed using the One-Step RT-ddPCR Advanced Kit
for Probes (Bio-Rad). The reaction mix contained a final 1 Supermix
concentration, 20 U/ml of reverse transcriptase, 15 mM DTT, 1 concen-
tration of rat PP1a or PP1g isoform-specific PCR primers and HEX flu-
orescent probe, and a 1 concentration of rat rplp0 PCR primers and
FAM fluorescent probe as a reference gene. Oil droplets were generated
using a QX200 automatic droplet generator (Bio-Rad), and 40ml of
droplets were transferred to a ddPCR 96-well plate (Bio-Rad), and the
plate was covered with a foil cover and sealed. The reverse transcriptase
reactions occurred at 50°C for 1 h in a C1000 Bio-Rad thermocycler.
Figure 1. P301L and R5L tau disrupt fast axonal transport in squid axoplasm model. A,
Vesicle motility assays in the isolated squid axoplasm were used to measure the effects of
tau proteins on FAT. Rate measurements (arrowheads, mm/s) from each independent experi-
ment are plotted as a function of time (minutes). Black arrowheads represent anterograde
FAT rates, and gray arrowheads represent retrograde FAT rates. Lines represent linear regres-
sion fits. WT tau monomer (2 mM, a near-physiological level) did not alter anterograde or
retrograde FAT rates. B, In contrast, perfusion of axoplasms with P301L tau monomers (2
mM) inhibited FAT rates in both directions. C, Perfusion with R5L tau monomers at 2mM also
inhibited anterograde and retrograde FAT rates. D, Quantitation of these effects revealed
that compared with perfusion with WT tau (1.51 6 0.07mm/s), perfusion of P301L tau
(1.31 6 0.08mm/s) or R5L tau (1.11 6 0.11mm/s) significantly decreased mean antero-
grade FAT rates. E, Perfusion of P301L (1.026 0.05mm/s) and R5L tau (0.886 0.17mm/
s) also decreased retrograde FAT rates compared with perfusion of WT tau (1.27 6
0.09mm/s). Statistical comparisons were made using a one-way ANOVA (WT tau, n = 6;
P301L tau, n = 4; R5L tau, n = 3); data indicate mean6 SD; *p 0.05).
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The PCR amplification protocol was 95°C for 10min to activate the
enzyme followed by 95°C for 30 s and 60°C for 60 s, repeated 40 with
ramp rates of 3°C/s. The enzyme was deactivated at 98°C for 10min and
held at 4°C. A QX200 Droplet Reader (Bio-Rad) was used to quantify
droplet fluorescence for each probe using the Absolute quantitation
function of QuantaSoft software (Bio-Rad). The software calculated con-
centrations of PP1 and rplp0 RNA (copies/ml) and reported as a ratio of
PP1 to the reference gene.
Axonal transport with PP1 knockdown. The neurons were trans-
fected with 175 ng of pCMV tau or GFP DNA, 175 ng of pH1SH shRNA
DNA, and 100ng of mApple-Synaptophysin DNA using Lipofectamine
2000, and the transport data collection and analysis was conducted using
conditions identical to those described above. The number of independ-
ent experimental replicates and total number of neurons analyzed were
as follows: WT tau 1 Control shRNA, n = 6, 11 neurons; WT tau 1
PP1a shRNA, n = 6, 9 neurons; WT tau1 PP1g shRNA, n = 6, 10 neu-
rons; P301L tau 1 Control shRNA, n = 6, 12 neurons; P301L tau 1
PP1a shRNA, n = 6, 10 neurons; P301L tau 1 PP1g shRNA, n = 6, 9
neurons; R5L tau 1 Control shRNA, n = 6, 10 neurons; R5L tau 1
PP1a shRNA, n = 6, 10 neurons; R5L tau 1 PP1g shRNA, n = 6, 9
neurons.
Experimental design and statistical analysis. Statistical analysis was
performed using GraphPad Prism 9. Comparisons within the tau groups
were made using one-way ANOVAs with Tukey’s post hoc multiple
comparison test (see Figs. 1, 6, 7A,B, 10). Repeated measures one-way
ANOVAs with the Geisser–Greenhouse correction to account for viola-
tions of the assumptions of sphericity (as indicated here by an «
value,0.5) and Tukey’s multiple comparison test were used for the cell
lysate immunoblots (see Figs. 5, 9). A repeated measures one-way
ANOVA with an assumption of sphericity and Tukey’s multiple com-
parison test were used to analyze the PLA quantitation (see Figs. 4, 8). A
repeated measures two-way ANOVA with an assumption of sphericity
and Tukey’s multiple comparison test was used for the pull-down assay
(see Fig. 2, tau groups and PP1/Halo groups). Repeated measures
ANOVAs were used to account for matching within datasets (e.g., cell
culture runs). Two-way ANOVAS with Tukey’s multiple comparison
test were used for comparisons in the nBRET assay (see Fig. 3, tau
groups and PP1/Halo groups) and axonal transport experiments with
PP1 knockdown (see Fig. 8, tau groups and shRNA groups). The p val-
ues reported from Tukey’s post hoc test within each ANOVA are
adjusted for multiple comparisons. Significance was established at p 
0.05. All experiments were performed three to six independent times,
and replicates are described in each figure legend and in Materials and
Methods. The horizontal lines and error bars represent mean6 SD.
Results
FTLDmutant tau impairs axonal transport in the squid
axoplasmmodel
Pathogenic forms of tau, including WT aggregates and several
disease-related monomeric forms of the protein, disrupted FAT
in a squid axoplasm model (Kanaan et al., 2011). This effect was
associated with changes in tau conformation that lead to aberrant
exposure of PAD in the amino terminus and activation of a sig-
naling pathway downstream of PP1 that has a negative impact
on kinesin-1-based anterograde FAT (LaPointe et al., 2009;
Kanaan et al., 2011; Cox et al., 2016; Tiernan et al., 2016).
Using vesicle motility assays in isolated squid axoplasm, we
first tested whether monomeric P301L or R5L mutant tau affects
FAT. Following perfusion of 2 mM monomeric WT tau, a near-
physiological concentration (Binder et al., 1985; Kanaan and
Grabinski, 2021), FAT rates remained unchanged for 50min
(Fig. 1A), as previously reported (Morfini et al., 2007; LaPointe
et al., 2009; Kanaan et al., 2011, 2012; Cox et al., 2016; Tiernan et
al., 2016). In contrast, FAT rates decreased in both anterograde
and retrograde directions on perfusion of axoplasms with 2 mM
monomeric P301L tau (Fig. 1B) or R5L tau (Fig. 1C). We
calculated the means of the rate readings over the last 20min of
the assay to identify any differences among the conditions.
Perfusion with P301L or R5L mutant tau significantly impaired
the rate of anterograde FAT when compared with WT tau (Fig.
1D; F(2,10) = 25.25, p = 0.0001; P301L vs WT, p = 0.0082; R5L vs
WT, p = 0.0001). P301L and R5L tau perfusion also reduced ret-
rograde FAT rates compared with WT tau (Fig. 1E; F(2,10) =
16.68, p = 0.0007; P301L vs WT, p = 0.0079; R5L vs WT, p =
0.0008). These data demonstrate that in the isolated axoplasm
preparation, both the P301L and R5L mutations confer on
monomeric tau a toxic effect on FAT.
The interaction between tau and PP1 is enhanced by the
P301L tau mutation
Next, we sought to evaluate whether tau interacts with any of
the three major PP1 isoforms in mammalian nerve tissues,
PP1a, PP1b , and PP1g1 (da Cruz e Silva et al., 1995). We began
by performing pull-down experiments using HEK293T cells
cotransfected with plasmids encoding PP1-HaloTag (N terminal)
or HaloTag proteins and WT, P301L, or R5L tau (C-terminal
NanoLuciferase-tagged; Fig. 2A). Immunoblotting experiments
showed no significant differences in tau or PP1 expression across
the conditions (Fig. 2B,D,F, Input). All tau proteins eluted in the
Halo-PP1a pull-down elution sample (Fig. 2B, red box, left), but
not with HaloTag alone (Fig. 2B, red box, right). Quantitative
data showed increased P301L tau levels in pull-down elution,
compared with WT and R5L tau, indicating enhanced binding of
mutant P301L tau to PP1a (Fig. 2C; Tau, F(2,6) = 7.348, p =
0.0244; PP1a, F(1,3) = 11.46, p = 0.0429; Interaction, F(2,6) =
7.339, p = 0.0244; P301L vs WT tau, p = 0.0311; P301L vs R5L
tau, p = 0.0198). We normalized the tau signal to the change in
Halo signal from before to after pull down (Fig. 2B, bottom)
because the HaloTag covalently binds the resin and does not
elute in these conditions. In the Halo-PP1b pull-down samples,
we detected trace amounts of tau (Fig. 2D), but the degree of
interaction was about fivefold lower than with PP1a or PP1g .
The P301L tau mutation did not significantly increase the inter-
action with PP1b compared with WT tau (Fig. 2E; Tau, F(2,6) =
5.093, p = 0.0509; PP1b , F(1,3) = 11.51, p = 0.0427; Interaction,
F(2,6) = 5.765, p = 0.0401; P301L vs WT tau, p = 0.1020) but did
compared with R5L tau (p = 0.0287). Finally, all three tau forms
eluted with the pull downs of the Halo-PP1g isoform (Fig. 2F).
Again, P301L tau induced a significant increase in binding effi-
ciency compared with WT and R5L tau (Fig. 2G; Tau, F(2,6) =
17.28, p = 0.0032; PP1g , F(1,3) = 30.89, p = 0.0115; Interaction,
F(2,6) = 16.86, p = 0.0034; P301L vs WT tau, p = 0.0033; P301L vs
R5L tau, p = 0.0008). Notably, the level of R5L pulled down with
PP1a (p = 0.9962), PP1b (p = 0.8256), or PP1g (p = 0.9999) was
unchanged when compared with WT, suggesting that this muta-
tion does not alter the extent of physical interaction between tau
and PP1. We did not detect tau in any of the control samples in
concurrent pull downs that were performed with HaloTag-only
(i.e., identical conditions other than no PP1 expression), which
effectively controls for nonspecific binding of HaloTag protein,
nonspecific interactions with the Halo-Link resin, and other ex-
perimental conditions. Collectively, these data suggest that tau
interacts with PP1a and PP1g and that this interaction is signifi-
cantly enhanced by the pathogenic P301L tau mutation but not
the R5L mutation.
Results from pull-down experiments provide evidence sup-
porting a protein–protein interaction between tau and selected
PP1 isoforms. We used nBRET assays to further evaluate this
interaction in living cells (Fig. 3A). This complementary approach
9436 • J. Neurosci., November 10, 2021 • 41(45):9431–9451 Combs et al. · FTLD-Tau and PP1 Impair Axonal Transport
avoids issues related to cell lysis before assess-
ing the interaction. First, we performed a do-
nor saturation assay by transfecting the cells
with a constant concentration of transfected
donor DNA and varied concentrations of
acceptor DNA. A specific interaction is indi-
cated by high-signal, hyperbolic curves that
display saturation of the nBRET ratios when
plotted against the DNA ratio (Mercier et al.,
2002). The nBRET ratio curves produced
from increasing Halo-PP1a with either WT,
P301L, or R5L tau (with C-terminal Nano
Luciferase tags) indicate specific interactions
between PP1a and each of the tau proteins
within cells (Fig. 3B). In contrast, nBRET
ratios generated from cells expressing Halo-
PP1b with any of the tau constructs did not
support interaction between the proteins
because of the overall low nBRET signal (Fig.
3C). Coexpression of Halo-PP1g with tau
produced curves indicating a specific interac-
tion with each of the tau forms (Fig. 3D).
The low level of interaction with PP1b com-
pared with PP1a and PP1g aligns well with
data from co-pull-down experiments (Fig. 2).
To control for potential nonspecific interac-
tions between tau-NanoLuc and the HaloTag
itself, we coexpressed the tau proteins with
the HaloTag protein alone and found no evi-
dence of specific interaction between any of
the tau proteins and the HaloTag (Fig. 3E).
We repeated the nBRET assay in four in-
dependent experiments at a single DNA ra-
tio of 100:1 to perform statistical
comparisons among tau groups and among
Halo-PP1 and the Halo-only control. The
nBRET ratios with P301L tau and Halo-
PP1a significantly increased compared with
WT and R5L tau with Halo-PP1a and sig-
nificantly increased for all tau groups com-
pared with the Halo-only control groups (Fig.
3F; Tau, F(2,18) = 58.78, p, 0.0001; Halo-
Figure 2. P301L mutation in tau enhances the interaction with PP1a and g isoforms in pull-down (PD) assays. A,
Schematic showing assay design. Individual tau constructs were coexpressed with HaloTag-PP1 (left) or HaloTag-only con-
trols (right) in HEK293T cells. Lysates prepared from these cells were incubated with HaloLink resin, which covalently binds
to HaloTag. We quantified the amount of tau signal (pan-tau R1 antibody, green) eluted from each pull down by immuno-
blot (PD elution) and normalized to the reduction in Halo signal (anti-Halo antibody, red) from prebinding to postbinding
lysate samples. B, WT, P301L tau, and R5L tau proteins were detected in the elution samples after a pull down with Halo-
PP1a (left, red box). Tau was not detected in the HaloTag-only control (right, red box). Lysate samples obtained before
(Input) and after pull down with the HaloLink resin (Post PD) were probed to confirm similar protein expression and
HaloTag binding to resin. C, Quantitation of tau in the elution samples indicate that P301L tau (0.673 6 0.429) signifi-
cantly increases the interaction with PP1a when compared with WT (0.1606 0.147) and R5L tau (0.1076 0.041) and
the control with HaloTag-only (WT tau, 0.0046 0.002; P301L, 0.0036 0.003; R5L, 0.003 6 0.001). D, A relatively low
level of WT and P301L tau was eluted from the Halo-PP1b pull down but not the HaloTag-only control. The pre- and
post-pull-down lysate samples from the Halo-PP1b and Halo-only lysates confirm similar expression and pull-down effi-
ciency. E, Quantitation of tau in the pull-down elution samples indicate that P301L tau (0.061 6 0.038) significantly
increases the interaction with PP1b when compared with the P301L1 HaloTag control (0.0016 0.001). Notably, the
amount of tau in the elution with Halo-PP1b pull down is much lower for all forms (WT tau, 0.0236 0.024; R5L, 0.009
/
6 0.005) and not significantly higher than the HaloTag-only
controls (WT tau, 0.001 6 0.001; R5L, 0.001 6 0.001). F,
WT and P301L tau proteins were detected in the elution sam-
ples after a pull down with Halo-PP1g . The pre- and post-
pull-down lysate samples from the Halo-PP1g and Halo-only
lysates confirm similar expression and pull-down efficiency. G,
Quantitation of tau in the elution samples indicate that P301L
tau (0.540 6 0.209) significantly increases the interaction
with PP1g when compared with WT tau (0.125 6 0.069),
R5L tau (0.111 6 0.075), and the P301L 1 HaloTag control
(0.000 6 0.001). Tau was also absent in HaloTag pull-down
controls (WT tau, 0.0016 0.002; R5L, 0.001 6 0.002). All
data in the legend are reported as ratios of the signal inten-
sities in arbitrary units. Statistical comparisons were performed
using a repeated measures two-way ANOVA with Tukey’s mul-
tiple comparison test, and each data point represents an inde-
pendent experimental replicate (n = 4 independent replicates;
data are mean6 SD; * p  0.05 for comparisons among the
tau group; #p  0.05 for the comparison between Halo-PP1
and Halo-only pull downs).
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PP1a, F(1,18) = 273.8, p, 0.0001; Interaction,
F(2,18) = 47.98, p, 0.0001; P301L vs WT tau,
p, 0.0001; P301L vs R5L tau, p, 0.0001;
Halo-PP1a vs Halo-only WT tau, p = 0.0006;
P301L tau, p, 0.0001; R5L tau, p = 0.0006).
None of the individual comparisons with
Halo-PP1b were statistically significant,
again suggesting a weak or nonexistent
interaction with this PP1 isoform (Fig. 3G;
Tau, F(2,18) = 2.381, p = 0.1209; Halo-PP1b ,
F(1,18) = 6.149,
p = 0.0233; Interaction, F(2,18) = 0.8514, p =
0.4433). Similar to PP1a, the nBRET ratio of
P301L tau and Halo-PP1g significantly
increased when compared with WT and R5L
tau, and all three tau proteins significantly
increased the ratio with Halo-PP1g coexpres-
sion compared with Halo-only controls (Fig.
3H; Tau, F(2,18) = 60.49, p, 0.0001; Halo-
PP1g , F(1,18) = 225.7, p, 0.0001; Interaction,
F(2,18) = 50.36, p, 0.0001; P301L vs WT tau,
p, 0.0001; P301L vs R5L tau, p, 0.0001;
Halo-PP1g vs Halo-only WT tau, p = 0.0009;
P301L tau, p, 0.0001; R5L tau, p = 0.0079).
The nBRET ratios for R5L were similar to
those for WT with PP1a (p = 0.9610), PP1b
(p = 0.9998) or PP1g (p = 0.9739), confirming
that this mutation does not alter the degree of
interaction in an in-cell assay. Considered to-
gether, these data indicate that when coex-
pressed in living cells, tau interacts with PP1a
and PP1g but only very weakly or not at all
with PP1b . Additionally, the P301L mutation
robustly enhances the interaction with PP1a
and PP1g compared with WT tau, whereas
the R5L mutation does not, which is consist-
ent with results from experiments in Figure 2.
Tau associates with endogenous PP1 in
mammalian neurons
After using an immortalized cell line to iden-
tify mutation- and isoform-specific effects,
we next wanted to identify interactions in
neurons. Using lentiviruses, we expressed the
various tau constructs in primary rat
Figure 3. Tau protein interacts with PP1a and PP1g , and the P301L tau mutation enhances the interaction in intracel-
lular nBRET assay. A, Tau proteins were tagged with a luciferase enzyme (NanoLuc) and coexpressed in HEK293T cells in
the presence of an individual Halo-PP1 isoform or HaloTag-only control protein. A fluorescent ligand binds to the HaloTag,
forming the acceptor molecule. Light emitted from the luciferase (donor) activates the fluorophore (acceptor) if they are
within;37 Å of each other because of a specific protein–protein interaction. The donor and acceptor signals were meas-
ured using filtered luminescence and reported as the nBRET ratio. The acceptor:donor DNA ratio was varied to generate a
donor saturation assay curve. B, The hyperbolic shape of the donor saturation curves indicated a specific protein–protein
interaction between Halo-PP1a and WT tau (solid black), P301L tau (solid gray), and R5L tau (dashed black) tagged with
NanoLuciferase. C, A strong interaction was not detected for the same forms of tau in the presence of Halo-PP1b . D, Each
form of tau displayed a clear interaction with Halo-PP1g . E, There was no evidence of a specific interaction between the
Halo-only control and any of the tau proteins. F, The nBRET was performed at an acceptor-to-donor DNA ratio of 100:1
with four independent replicates to compare nBRET ratios among the tau groups with Halo-PP1 or Halo-only. Each tau dis-
played significantly higher nBRET ratios with Halo-PP1a (WT tau, 9.57 6 1.05 mBU; P301L, 20.40 6 2.58 mBU; R5L,
10.25 6 0.57 mBU) compared with Halo-only controls (WT tau, 5.168 6 0.16 mBU; P301L, 5.814 6 0.36 mBU; R5L,
/
5.4186 0.30 mBU). P301L tau nBRET ratios were significantly
higher than WT and R5L tau with Halo-PP1a. G, There was
no significant increase detected for any of the individual tau
constructs with Halo-PP1b (WT tau, 6.067 6 1.69 mBU;
P301L, 8.323 6 2.59 mBU; R5L, 6.325 6 1.53 mBU) com-
pared with Halo-only or among the tau constructs and Halo-
PP1b . H, The nBRET ratios for each of the tau forms were sig-
nificantly higher with Halo-PP1g (WT tau, 9.5796 0.4296
1.71 mBU; P301L, 20.38 6 1.99 mBU; R5L, 8.939 6 1.37
mBU) compared with Halo-only controls. The nBRET ratios
between Halo-PP1g and P301L tau significantly increased
compared with WT and R5L tau. Statistical comparisons for F–
H were performed using a two-way ANOVA with Tukey’s mul-
tiple comparison test, and each data point represents an inde-
pendent experimental replicate (data are mean 6 SD; *p 
0.05 for the comparison among the tau groups; #p 0.05 for
the comparison between Halo-PP1 and Halo-only groups).
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hippocampal neuron cultures, which typically produce low levels
of overexpression. We used PLA to identify relative differences in
the association between tau and PP1 in the neurons expressing
WT, P301L, and R5L tau. The assay uses antibody pairs that
selectively recognize putative interactor proteins. Secondary antibod-
ies, linked to complementary oligonucleotide sequences, bind the
primary antibodies. The complementary oligo sequences are ligated
in situ if the primary antibody epitopes from the two proteins are
Figure 4. P301L tau increases the association with PP1 in primary hippocampal neurons. A, Lentiviruses were used to express WT, P301L, or R5L tau in cultured primary rat hippocampal neurons
beginning at DIV 4 and fixed in 4% paraformaldehyde on DIV 8. The neurons were probed with Tau7 (C-terminal tau epitope) and a PP1 antibody before performing the PLA staining procedure
that demonstrates a close association between these proteins (,40 nm) indicated by a green fluorescent punctate signal. Following PLA, the cells underwent immunocytofluorescence staining with
a Tau12 (red, human tau-specific N-terminal tau epitope) to identify exogenous tau and Tuj1 (cyan) to identify neurons and neuron processes. B, The PP1 antibody recognizes recombinant PP1a,
PP1b , and PP1g in an immunoblot (green), and a 6 His antibody labels total protein. C, Images of isolated neurons were used to quantify puncta per area of Tau12 staining (i.e., transduced
neurons). P301L tau-expressing neurons (67.36 17.7 puncta/nm2) showed significantly greater PLA signal than WT (23.16 8.5 puncta/nm2) and R5L tau-expressing neurons (31.36 9.8 puncta/
nm2), complementing results obtained in HEK cell pull down and NanoBRET assays (Figs. 2, 3). Data represent mean 6 SD and were analyzed using repeated measures one-way ANOVAs and
Tukey’s post hoc multiple comparison test, *p 0.05. D–F, PLA detected associations between WT tau and endogenous rat PP1 (PLA, green puncta; Tau12, red), in both neuronal processes (E) and
cell bodies (F). G–I, Neurons expressing P301L tau displayed an enhanced association between tau and PP1 as evidenced by the PLA puncta, which were found in processes (H) and cell bodies of
neurons (I). J–L, Neurons expressing R5L tau showed an association between tau and PP1 that was similar to WT tau cells and localized to neuronal processes (K) and cell bodies (L). M–O, Primary
antibody delete controls included omission of either Tau7 (M), PP1 (N), or both (O). Primary delete controls showed little to no nonspecific background signal. P–R, PLA in untransduced neurons
(No LV) demonstrated an association between endogenous rat tau and PP1, which were evident in neuronal processes (Q) and cell bodies (R) of neurons. Scale bars: 20mm for all images.
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Figure 5. FTLD mutant tau enhances the levels of active PP1 in cells and primary neurons. A, Immunoblotting confirmed expression of GFP, WT, P301L, and R5L tau in HEK293T
cells coexpressing PP1a. B, Quantification of tau bands indicated similar levels of tau across the three constructs (WT tau, 4.87 6 0.36; P301L, 5.73 6 0.58; R5L: 5.67 6 0.66). C,
Immunoblots of total PP1 (green, HaloTag antibody) and inactive PP1 (red, phospho-Thr320 PP1 antibody). D, Quantification of PP1 blots showed that P301L tau increased levels of
active PP1a (as indicated by reduced inactive pT320 PP1 signal) compared with GFP control (GFP, 0.731 6 0.331; WT tau, 0.627 6 0.054; P301L, 0.388 6 0.066; R5L, 0.409 6
0.121). E, Immunoblots of GFP and tau in cell lysates coexpressing PP1b . F, Quantification of tau bands indicated similar expression of tau (WT tau, 7.58 6 1.66; P301L, 7.94 6
1.15; R5L, 9.726 3.72). G, Immunoblots of total PP1 (green) and inactive pT316 PP1b (red). H, Quantification of PP1 blots showed that expression of any of the three forms of tau
significantly increased active PP1b levels (i.e., reduced inactive pT316 PP1b ) compared with GFP control (GFP, 0.0155 6 0.0017; WT tau, 0.0123 6 0.0019; P301L, 0.0084 6
0.0013; R5L, 0.00656 0.0003). P301L and R5L tau significantly increased active PP1b compared with WT tau as well. I, Immunoblots of cells coexpressing GFP, WT tau, P301L tau,
or R5L tau and PP1g . J, Quantification of tau bands showed similar tau expression levels (WT tau, 13.4 6 3.3; P301L, 15.9 6 3.4; R5L, 21.6 6 11.8). K, Immunoblots of total PP1
(green) and inactive pT311 PP1g (red). L, Quantification of PP1 blots demonstrated that expression of all forms of tau increased active PP1g (i.e., reduced inactive pT311 PP1g ;
GFP, 0.0453 6 0.0142; WT tau, 0.0161 6 0.0030; P301L, 0.0045 6 0.0013; R5L, 0.0065 6 0.0026). M, Immunoblot of lysates from rat primary neurons expressing GFP or tau (WT,
P301L, or R5L) via lentiviral transduction probed with tau (green) and GFP (red) and a loading control (GAPDH). N, Quantification of the exogenous tau bands (top, green) indicated
9440 • J. Neurosci., November 10, 2021 • 41(45):9431–9451 Combs et al. · FTLD-Tau and PP1 Impair Axonal Transport
near each other (,40nm). Following amplification and hybridiza-
tion with fluorescent oligonucleotides, ligated oligos are indicated by
bright puncta (Fig. 4A, green).
We probed neurons with Tau7, a mouse monoclonal anti-
body that binds to the C terminus of tau (Horowitz et al., 2004)
and a PP1 rabbit polyclonal antibody that recognizes all PP1 iso-
forms in an immunoblot (Fig. 4B). Quantification of the PLA
signal indicated that the P301L mutation enhanced the associa-
tion between tau and PP1 compared with WT and R5L tau (Fig.
4C; F(2,4) = 42.97, p = 0.0020; P301L vs WT tau, p = 0.0021;
P301L vs R5L, p = 0.0046). Neurons expressing WT human tau
presented PLA puncta, indicating a tau-PP1 association in neu-
rites and cell bodies (Fig. 4D–F). We identified increased concen-
trations of puncta in neurons expressing P301L tau that also
localized to neurites and soma (Fig. 4C,4G–I). R5L-expressing
neurons also displayed puncta with similar patterns of subcellu-
lar localization, but there was no increase compared with WT
(Fig. 4C,J–L). The control conditions included primary antibody
deletions of Tau7 (Fig. 4M), PP1 (Fig. 4N), and both antibodies
(Fig. 4O), all of which showed little to no background signal in
the neurons. Finally, we identified associations between endoge-
nous rat tau and PP1 in nontransduced cells (Fig. 4P–R). These
results strongly support an interaction between tau and PP1 in
mammalian neurons under physiological conditions. WT tau
and both mutants interact with PP1, but the P301L mutation
increases the binding of PP1 to tau relative to WT, whereas the
R5L mutation does not increase PP1 binding over WT tau.
FTLD-tau mutations increase levels of active PP1
After establishing tau interactions with PP1a and PP1g , we
determined whether tau also affected levels of active PP1 in
cells cotransfected with GFP, WT, P301L, or R5L tau. First,
we confirmed that similar levels of tau expression, normal-
ized to GAPDH levels, were present in the experiments with
PP1a coexpression (Fig. 5A,B; F(1.585,4.754) = 2.764, p =
0.1610). Next, we probed lysates by immunoblotting using
an anti-pT320 PP1 antibody that recognizes the inhibitory
phosphoT320 site in PP1a and analogous sites T316 in PP1b
and T311 in PP1g (Dohadwala et al., 1994; Hou et al., 2013),
as well as a phosphorylation-independent anti-HaloTag anti-
body (Total PP1). P301L tau significantly increased the level
of active PP1a (as indicated by reduced inactive pT320 PP1a
signal normalized to total PP1a signal), compared with WT-
tau-expressing cells (Fig. 5C,D; F(1.410,4.229) = 4.705, p =
0.0885; P301L vs WT tau, p = 0.0031) but none of the other
comparisons were statistically different (R5L vs WT tau, p =
0.1698). We confirmed similar levels of tau expression in the
PP1b experiments (Fig. 5E,F; F(1.095,3.286) = 0.9685, p =
0.4025). Expressing each of the mutant tau proteins led to a
significant increase in the level of active PP1b when com-
pared with GFP and WT tau (Fig. 5G,H; F(1.693,5.080) = 41.45,
p = 0.0008; P301L tau vs GFP, p = 0.0216; R5L tau vs GFP,
p = 0.0029; P301L vs WT tau, p = 0.0236; R5L vs WT tau,
0.0211). We then expressed similar levels of tau with PP1g
(Fig. 5I,J; F(1.113,3.338) = 1.128, p = 0.3696). Again, both P301L
and R5L mutant tau proteins significantly increased the levels of
active PP1g compared with GFP and WT tau (Fig. 5K,L;
F(1.048,3.143) = 30.28, p = 0.0103; P301L tau vs GFP, p = 0.0262;
R5L tau vs GFP, p = 0.0328; P301L vs WT tau, p = 0.0070; R5L
vs WT tau, p, 0.0001). These results show that P301L or R5L
mutant coexpression with PP1 reduced levels of T320 phospho-
rylation in PP1b and PP1g isoforms compared with control
conditions (i.e., GFP and WT tau), and P301L tau expression
reduced it in PP1a compared with GFP expression. This suggests
that these FTLD-tau mutants are associated with increased levels
of active PP1 in HEK293T cells.
After identifying the effect of tau on active PP1 levels in the
HEK293T cell line, we set out to measure these effects on endog-
enous PP1 in primary rat hippocampal neurons by individually
expressing the three tau constructs or a GFP control via lentiviral
transduction. We immunoblotted the neuron lysates to confirm
equal levels of protein loading and tau expression (Fig. 5M,N;
F(1.270,3.810) = 3.013, p = 0.1632). Then we probed the lysates with
the anti-pT320 PP1 antibody and a total PP1 antibody (Fig.
5O). Expression of P301L tau and R5L tau increased levels of
active PP1 (indicated by decreased inactive pT320 PP1) com-
pared with GFP-expressing neurons (Fig. 5P; F(1.559,4.677) =
7.053, p = 0.0420; P301L tau vs GFP, p = 0.0403; R5L tau vs
GFP, p = 0.0468). In contrast, WT tau expression did not sig-
nificantly alter active PP1 levels (p = 0.9962). This supports an
increase in active PP1 levels following expression of FTLD
mutant tau, but not WT tau.
FTLDmutant tau impairs axonal transport in mammalian
neurons
Next, we tested whether our findings about the effects of tau on
FAT in the squid axoplasm extended to mammalian cultured
neurons. We cotransfected rat primary hippocampal neurons
with mApple-synaptophysin (an established cargo protein of
synaptic vesicle precursors) and either WT, P301L, or R5L mu-
tant tau or a GFP control construct (Fig. 6A). Using live cell con-
focal microscopy to image vesicle transport along the axon (;28
frames/s; Fig. 6B) we then measured transport characteristics via
kymograph analysis (Fig. 6C). In GFP-expressing and all tau-
expressing neurons, fluorescently tagged synaptic vesicle precur-
sors displayed similar anterograde FAT rates (as indicated by the
anterograde segment velocity; Fig. 6D; F(3,19) = 1.369, p =
0.2824). When compared with GFP cells, we detected a small but
significant increase in retrograde FAT rates (;20%) in neurons
expressing each of the tau proteins (Fig. 6E; F(3,19) = 5.900, p =
0.0051; WT tau vs GFP, 0.0353; P301L tau vs GFP, p = 0.0103;
R5L tau vs GFP, 0.0104). We also analyzed the impact of tau
expression on the pause frequency of fluorescently labeled
vesicles, as PP1 activation by pathogenic tau promotes detach-
ment of kinesin-1 from its transported organelle cargoes
(Morfini et al., 2002; Kanaan et al., 2011). Compared with GFP
control, WT tau did not significantly alter cargo pause frequency
(Fig. 6F; F(3,19) = 32.58, p, 0.0001; WT tau vs GFP: p = 0.9034).
In contrast, P301L tau expression significantly increased the fre-
quency of cargo pauses compared with both GFP (p, 0.0001)
and WT tau (p, 0.0001, as did R5L tau expression compared
with both GFP and WT tau (both p, 0.0001). To evaluate
/
similar levels of tau across the three constructs (WT tau, 19.2 6 3.9; P301L, 14.8 6
2.6; R5L, 17.4 6 4.6). O, Immunoblot of total PP1 (green, PP1 antibody) and inactive
PP1 (red, pThr320 PP1 antibody). P, Quantification of the immunoblots demonstrated
that P301L tau and R5L tau expression increased levels of active PP1 (i.e., reduced inac-
tive pT320 PP1) compared with a control GFP expression, whereas WT tau did not signif-
icantly change active PP1 levels (GFP, 0.0192 6 0.0012; WT tau, 0.0190 6 0.0029;
P301L, 0.0159 6 0.0006; R5L, 0.0162 6 0.0015). Note that tau signal was normalized
to GAPDH loading control (B, F, J, N), and pT320 PP1 signal was normalized to total
PP1 signal (D, H, L, P). Data in figure legend are reported in ratios of the signal inten-
sities in arbitrary units. All data are mean 6 SD and were compared using repeated
measures one-way ANOVAs with a Geisser–Greenhouse correction and Tukey’s post hoc
multiple comparison test, *p  0.05).
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Figure 6. P301L and R5L tau increase axonal transport pause frequency in primary rat hippocampal neurons. A, Neurons were cotransfected with an mApple-synaptophysin (mA-Syn) fusion
construct and GFP, WT tau, P301L tau, or R5L tau. Axons were identified in live cells by labeling an external region of neurofascin (NF, left, cyan). After fixation cotransfection of both constructs
was identified in all cells (right). Scale bar, 50mm. B, Axonal transport of fluorescent vesicles was imaged at 28 fps for 5 min. Each panel in this image is 1 s after the previous one. Scale bar,
28mm. The solid arrows track a vesicle moving in the anterograde direction, and the wire arrows track a vesicle moving in retrograde direction before pausing. C, Kymographs were generated
and analyzed using the KymoAnalyzer macro for ImageJ. The parameters included direction, segment velocities, and pause frequency. Anterograde tracks are labeled green, retrograde tracks
area labeled red, and tracks that switch direction are labeled yellow. D, The mean anterograde segment velocity was not significantly affected by expression of GFP or any of the tau proteins
tested (GFP, 2.226 0.22mm/s; WT tau, 2.446 0.43mm/s; P301L, 2.496 0.27mm/s; R5L, 2.586 0.28mm/s). E, Expression of WT, P301L, or R5L tau caused a small but significant eleva-
tion in retrograde velocity (;20%) when compared with GFP control but no significant differences were detected between the three tau proteins (GFP, 2.016 0.24mm/s; WT tau, 2.386
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directionality-related effects on FAT, we further separated total
pause frequency data for cargo traveling in the anterograde or
retrograde directions. Expression of P301L tau or R5L tau signifi-
cantly increased anterograde pause frequency compared with
both GFP- and WT tau-expressing neurons (Fig. 6G; F(3,19) =
5.990, p = 0.0047; P301L vs GFP, 0.0471; P301L vs WT tau, p =
0.0345; R5L tau vs GFP, p = 0.0341; R5L tau vs WT tau, p =
0.0252). Retrograde pause frequency also increased with expres-
sion of P301L tau compared with GFP (p = 0.0064) and WT tau
(p = 0.0178; Fig. 6H; F(3,19) = 8.853, p = 0.0007) and R5L tau
induced the same effects (R5L tau vs GFP, p = 0.0045; R5L tau vs
WT tau, p = 0.0120). These data suggest that although WT tau
expression does not have an impact on cargo pausing, mutant
P301L tau and R5L tau expression significantly increase cargo
pause frequency. On the other hand, FAT rates were unaltered
(anterograde FAT) or slightly increased (retrograde FAT) by all
three forms of tau compared with control conditions.
FTLDmutant tau impairs FAT via a PP1c-dependent
mechanism in hippocampal neurons
Next, we determined whether the P301L tau-induced effect on
FAT documented in Figure 6 was dependent on PP1. We
designed PP1 isoform-specific shRNAs to knock down expres-
sion of either PP1a or PP1g because those isoforms displayed a
clear interaction and activation with tau in our previous assays.
Isoform-specific knockdown provides specificity while helping
avoid toxic effects elicited by pharmacological PP1 inhibitors
that target all isoforms. To confirm effectiveness of each shRNA,
we measured shRNA-mediated knockdown of a Renilla lucifer-
ase-PP1 isoform fusion construct in a dual luciferase assay. The
PP1a shRNA produced 87% knockdown when compared with
controls expressing the reporter. The control nontargeting
shRNA did not significantly alter expression when compared
with the empty controls (i.e., 103% of control; Fig. 7A). The
PP1g shRNA produced 90% knockdown, whereas the signal
with control shRNA was 102% of empty vector controls (Fig.
7B). To confirm knockdown in rat primary neurons we trans-
duced them with lentiviruses expressing PP1a-shRNA, PP1g -
shRNA, or control shRNA. Using ddPCR we determined the
mRNA concentrations from cell lysates under each condition,
then normalized them to rplp0 reference gene concentrations.
The ddPCR analysis showed that PP1a mRNA levels were
reduced 71% by PP1a-specific shRNA and only 19% by PP1g -
specific shRNA compared with the control shRNA (Fig. 7C).
Similarly, PP1g mRNA levels were reduced 70% by PP1g -spe-
cific shRNA expression and only 9% by PP1a-specific shRNA
when compared with the control shRNA treatment (Fig. 7D).
These data validate that each PP1 isoform-specific shRNA
produces target knockdown with low off-target (i.e., other PP1
isoform) effects in cultured hippocampal neurons.
Having established the knockdown specificity and effective-
ness of shRNAs, we performed triple transfections of primary rat
hippocampal neurons aimed at coexpressing (1) shRNA target-
ing PP1a or PP1g or the nontargeting control shRNA; (2) WT,
P301L, or R5L tau; and (3) mApple-synaptophysin in the various
combinations. The PP1 isoform-specific shRNAs did not signifi-
cantly affect anterograde transport velocity (Fig. 7E; Tau, F(2,45) =
1.128, p = 0.3325; shRNA, F(2,45) = 5.053, p = 0.0105; Interaction,
F(4,45) = 0.1333, p = 0.9693). R5L tau produced a small but signif-
icant increase in retrograde FAT compared with WT tau in the
control shRNA condition (Fig. 7F; Tau, F(2,45) = 1.999, p =
0.1473; shRNA, F(2,45) = 3.788, p = 0.0302; Interaction, F(4,45) =
1.148, p = 0.3464; R5L vs WT tau, p = 0.0333). These data indi-
cate that exogenous tau expression did not affect FAT rates sig-
nificantly, regardless of shRNA treatment groups.
We next examined whether PP1 shRNAs abolished the mu-
tant-tau-induced effects on cargo pausing frequency. As expected
from results in Figure 6, expressing P301L tau or R5L tau in the
presence of control shRNA led to significantly increased total
pause frequency compared with neurons expressing WT tau and
control shRNA (Fig. 7G; Tables 1, 2; Tau, F(2,45) = 17.61,
p, 0.0001; shRNA, F(2,45) = 16.61, p, 0.0001; Interaction, F(4,45) =
4.463, p = 0.0040). Compared with expression of WT tau, the PP1a
shRNA did not significantly modify the increase in total pause
frequency induced by mutant tau expression (Fig. 7G). In con-
trast, PP1g shRNA significantly reduced the total pause fre-
quency in P301L- and R5L-expressing neurons to levels observed
in WT neurons with control shRNA (Fig. 7G, dotted line). These
data indicate that the increase in FAT pause frequency induced
by P301L or R5L tau expression is eliminated by specific knock-
down of PP1g , but not PP1a.
To further investigate the specificity of mutant tau effects on
cargo pausing and the relationship of these effects to PP1g
knockdown, pause frequencies were binned for cargo traveling
in the anterograde or retrograde FAT directions. Here, we found
that PP1g knockdown rescued mutant-tau-induced pausing
defects in the anterograde direction. As observed with no shRNA
treatments (Fig. 6G–I), expression of P301L tau significantly
increased anterograde pause frequency (Fig. 7H; Tables 1, 2; Tau,
F(2,45) = 15.80, p, 0.0001; shRNA, F(2,45) = 20.94, p, 0.0001;
Interaction, F(4,45) = 2.133, p = 0.0923) compared with cells
expressing WT tau with control shRNA treatment. Knockdown
of PP1a did not alter this effect. In contrast, treating the P301L-
or R5L-expressing neurons with PP1g -shRNA eliminated the
increased anterograde pause frequency, restoring pausing to WT
tau levels (Fig. 7H).
We detected similar effects of tau expression on retrograde
pause frequency, albeit lower in magnitude (Fig. 7I; Tables 1, 2;
Tau, F(2,45) = 5.193, p = 0.0093; shRNA, F(2,45) = 9.244, p =
0.0004; Interaction, F(4,45) = 3.921, p = 0.0082). As expected,
P301L or R5L expression increased retrograde cargo pause fre-
quency with control shRNA coexpression. We did not observe
significant differences among any of the tau groups with knock-
down of PP1a, likely because of the nonsignificant elevation in
pause frequency noted with PP1a shRNA (observed with total,
anterograde, and retrograde pausing). Again, PP1g shRNA com-
pletely prevented the increase in retrograde pause frequency in
P301L- and R5L-expressing neurons. Collectively, these data
indicate that P301L and R5L tau produce pause frequency abnor-
malities in both directions and that specifically knocking down
PP1g robustly alleviates these abnormalities.
/
0.28mm/s; P301L, 2.45 6 0.15mm/s; R5L, 2.47 6 0.15mm/s). F, Expression of either
P301L or R5L tau resulted in an increase of total pause frequency (number of pauses/track/s)
compared with GFP and WT tau expression (GFP, 0.1606 0.040 pauses/s; WT tau, 0.1786
0.039 pauses/s; P301L, 0.326 6 0.039 pauses/s; R5L, 0.370 6 0.057 pauses/s). G,
Anterograde pause frequency (pauses in cargo traveling in the anterograde direction)
increased with P301L and R5L tau expression compared with GFP and WT tau (GFP, 0.143
6 0.044 pauses/s; WT tau, 0.137 6 0.043 pauses/s; P301L, 0.241 6 0.080 pauses/s; R5L,
0.252 6 0.067 pauses/s). H, The retrograde pause frequency also increased on P301L and
R5L tau expression compared with GFP and WT tau (GFP, 0.107 6 0.015 pauses/s; WT tau,
0.116 6 0.046 pauses/s; P301L, 0.180 6 0.021 pauses/s; R5L, 0.187 6 0.043 pauses/s).
The groups were compared using a one-way ANOVA with Tukey’s multiple comparison test,
and each data point represents an independent replicate (n = 6 for GFP, WT tau, and P301L
tau and n = 5 for R5L tau; the data are the mean6 SD; *p 0.05).
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Figure 7. PP1g knockdown rescues the effects of P301L and R5L on fast axonal transport pause frequency in primary neurons. PP1 expression was knocked down using isoform-specific
shRNAs. The shRNAs were validated using a Renilla-Firefly Luciferase assay in HEK293T cells. Renilla-PP1 fusion constructs were cotransfected with shRNAs targeting Renilla (positive control), a
nontargeting shRNA sequence (Control shRNA; used as a negative control), or specific PP1 isoforms. Expression knockdown is reported as percentage of an empty shRNA vector control. A,
PP1a shRNA produced 87% knockdown from control levels. B, PP1g shRNA induced 90% knockdown from control levels. Data were compared (A–B) using a one-way ANOVA with Tukey’s
multiple comparison test, and each data point represents an independent replicate (n = 3; data are mean 6 SD; *p  0.05). C, Neuronal mRNA knockdown was validated using lentiviral
expression of PP1a-shRNA, PP1g -shRNA, or the control shRNA. PP1a and PP1g mRNA concentrations were determined using ddPCR and normalized to rplp0 reference gene expression.
PP1a shRNA treatment knocked down PP1a mRNA compared with control shRNA treatment, whereas PP1g shRNA treatment only minimally reduced it. D, PP1g shRNA knocked down
PP1g mRNA compared with control shRNA treatment, whereas PP1a shRNA slightly reduced it. Error bars in C and D represent the 95% confidence intervals. E, Transport experiments were
repeated with PP1a, PP1g -, or control shRNA. Anterograde segment velocity was not significantly different among any of the conditions. Dotted lines represent the baseline values (i.e., the
mean of values in the WT tau1 control shRNA treatment condition for E and F. F, Retrograde segment velocity was slightly higher with R5L expression compared with WT tau with control
shRNA. G, Expressing P301L tau or R5L tau increased total pause frequency compared with WT tau when treated with control or PP1a-shRNA. In contrast, PP1g -shRNA treatment rescued
P301L- and R5L-induced increases in pause frequency by reducing total pause frequency to WT tau control levels. H, P301L and R5L tau increased anterograde pause frequency compared with
WT tau1 control or PP1a-shRNA. Treatment with PP1g -shRNA reduced anterograde pause frequency in P301L and R5L neurons compared with WT tau neurons. I, P301L and R5L expression
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P301L tau increases association with the PP1c isoform in
primary neurons
We repeated the PLA experiments with an antibody that specifi-
cally recognizes the PP1g isoform to confirm an association
between it and tau as well as to determine how FTLD mutations
alter the association (Fig. 8A). Expression of P301L tau in the
neurons increased PLA puncta compared with WT tau expres-
sion (Fig. 8B; F(2,4) = 8.785, p = 0.0344; P301L vs WT tau, p =
0.0326). No significant differences existed between WT tau and
R5L tau (p = 0.5210). Primary deletion of the various antibodies
resulted in little to no background signal (Figs. 4N,O, 8C). WT
tau-expressing neurons displayed PLA puncta (Fig. 8D), present
in the neuronal processes (Fig. 8E) and cell bodies (Fig. 8F) indi-
cating an association with the PP1g isoform specifically.
Expression of mutant P301L tau increased the number of puncta
compared with WT tau expression (Fig. 8G–I). R5L tau also
interacted with PP1g in the neurons at similar levels to WT tau
(Fig. 8J–L). Notably, these findings mirror the neuron PLA data
using a pan-PP1 antibody (Fig. 4) and the data from HEK293T
cells (Figs. 2, 3). We also identified associations between endoge-
nous rat tau and PP1g in untransduced neurons (Fig. 8M–O).
Together, this supports a neuronal association between tau and
the PP1g isoform, found to be the mediator of the mutant-tau-
induced effects on FAT (Fig. 7).
FTLDmutant tau impairs FAT via a PAD-dependent
mechanism in hippocampal neurons
Previously, the PAD (amino acids 2–18 in tau) was identified as
necessary and sufficient to induce PP1-dependent transport
defects in the squid axoplasm (LaPointe et al., 2009; Kanaan et
al., 2011). Disease-relevant tau modifications are associated with
conformation changes in this region that are early markers of tau
dysfunction in tauopathies (Kanaan et al., 2011; Combs et al.,
2016; Combs and Kanaan, 2017). We first sought to determine
the relevance of PAD to the activation of PP1 by deleting amino
acids 2–18 in both WT and P301L tau then expressing them with
individual PP1 isoforms. We confirmed similar levels of tau
expression, normalized to GAPDH loading control, for experi-
ments with PP1a (Fig. 9A,B; F(1.141,3.423 = 4.431, p = 0.1146; WT
tau vs D2–18 WT tau, p = 0.0113), PP1b (Fig. 9E,F; F(1.066,3.197 =
0.2118, p = 0.6896), and PP1g (Fig. 9I,J; F(1.287,3.860 = 1.269, p =
0.3455). Expressing D2–18 WT tau and D2–18 P301L tau
resulted in reduced active PP1a (i.e., higher inactive PP1a to
total PP1) compared with full-length counterparts (Fig. 9C,D;
F(1.532,4.595 = 27.27, p = 0.0033; WT tau vs D2–18 WT tau, p =
0.0018; P301L tau vs D2–18 P301L tau, p = 0.0463). Importantly,
PAD deletion rescued the P301L-induced change from WT tau
(WT tau vs P301L, p = 0.0276; D2–18 P301L tau vs WT tau, p =
0.2834). Similarly, P301L tau resulted in an increase in active
PP1b compared with WT tau (p = 0.0232), and deletion of PAD
reduced active PP1b for both WT and P301L tau (Fig. 9G,H;
F(1.301,3.904 = 106.0, p = 0.0005; WT tau vs D2–18 WT tau, p =
0.0113; P301L tau vs D2–18 P301L tau, p = 0.005). Finally, we
detected lower levels of active PP1g with D2–18 WT tau com-
pared with full-length tau expression (Fig. 9K,L; F(1.034,3.102 =
19.12, p = 0.0205; WT tau vs D2–18 WT tau, p = 0.0196). P301L
tau induced a significant increase in active PP1 compared with
WT tau (p = 0.0092), and PAD deletion in a P301L background
caused a ninefold reduction in active PP1g that did not reach
statistical significance (p = 0.1531) and a return to levels that
were not significantly different from WT tau (p = 0.7579). These














WT tau 1.81 6 0.33 1.93 6 0.22 0.155 6 0.038 0.072 6 0.028 0.121 6 0.025
P301L tau 2.00 6 0.37 2.24 6 0.27 0.356 6 0.109 0.184 6 0.055 0.206 6 0.085
R5L tau 2.10 6 0.34 2.32 6 0.34 0.336 6 0.112 0.206 6 0.057 0.226 6 0.086
PP1a shRNA
WT tau 2.22 6 0.36 2.26 6 0.11 0.222 6 0.039 0.158 6 0.049 0.169 6 0.025
P301L tau 2.30 6 0.56 2.36 6 0.27 0.339 6 0.051 0.230 6 0.063 0.237 6 0.022
R5L tau 2.30 6 0.20 2.24 6 0.25 0.324 6 0.059 0.253 6 0.082 0.175 6 0.040
PP1g shRNA
WT tau 1.85 6 0.43 2.01 6 0.29 0.168 6 0.032 0.089 6 0.019 0.126 6 0.035
P301L tau 1.96 6 0.30 2.08 6 0.30 0.156 6 0.020 0.087 6 0.010 0.106 6 0.015
R5L tau 2.00 6 0.15 2.06 6 0.21 0.227 6 0.035 0.139 6 0.046 0.155 6 0.043
This table includes mean values 6 SD for axonal transport directional segment velocities and total and directional pause frequencies from the tau expression groups within each shRNA treatment group (Fig. 7E–I).
/
increased retrograde pause frequency compared with WT tau with control shRNA treatments.
Coexpression of WT, P301L, or R5L tau with PP1a-shRNA were not different likely because
of the enhanced pause frequency in WT. With P301L and R5L, PP1g -shRNA reduced retro-
grade pause frequency to levels similar to WT with PP1g -shRNA and to baseline levels (i.e.,
WT with control shRNA). Data were compared (E–I) using a two-way ANOVA with Tukey’s
multiple comparison test to compare the three tau groups within each individual shRNA treat-
ment group, and each data point represents an independent replicate (n = 6; the data are
mean6 SD; *p 0.05; Table 1, mean6 SD; Table 2, for statistical p values).
Table 2. Two-way ANOVA Tukey’s post hoc multiple comparison analysis for tau
1 shRNA axonal transport pause frequency data
Comparison Total Anterograde Retrograde
Control shRNA
WT tau versus P301L tau p, 0.0001 p = 0.0100 p = 0.0109
WT tau versus R5L tau p, 0.0001 p, 0.0001 p = 0.0014
P301L tau versus R5L tau p = 0.8466 p = 0.7316 p = 0.7547
PP1a shRNA
WT tau versus P301L tau p = 0.0073 p = 0.0450 p = 0.0536
WT tau versus R5L tau p = 0.0209 p = 0.0058 p = 0.9797
P301L tau versus R5L tau p = 0.9163 p = 0.7061 p = 0.0821
PP1g shRNA
WT tau versus P301L tau p = 0.9457 p = 0.9974 p = 0.7415
WT tau versus R5L tau p = 0.2491 p = 0.2119 p = 0.5665
P301L tau versus R5L tau p = 0.1406 p = 0.1875 p = 0.1939
This table includes the adjusted p values for the comparisons between tau expression groups within each
shRNA treatment group for axonal transport total and directional pause frequencies. Data (Fig. 7G–I) was
analyzed by two-way ANOVA with Tukey’s multiple comparison test. Significance was established at an
adjusted p  0.05.
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indicate that generally the PAD region in the N terminus of tau
mediates its effects on increasing levels of active PP1.
Finally, we examined the role of PAD on the alterations in
FAT of cargoes containing mApple-synaptophysin in primary
rat neurons. We individually coexpressed full-length and D2–18
versions of WT and P301L tau with the synaptophysin construct
then imaged and analyzed transport as above. Deletion of amino
acids 2–18 did not influence anterograde (Fig. 10A; F(3,16) =
2.431, p = 0.1029) or retrograde (Fig. 10B; F(3,16) = 0.2275, p =
0.8758) velocities. Again, P301L tau increased total pause fre-
quency compared with WT tau (Fig. 10C; F(3,16) = 13.59, p =
0.0001; WT tau vs P301L tau, p = 0.0009) and PAD deletion res-
cued pause frequency to control levels (WT tau vs D2–18 P301L
tau, p = 0.9815; P301L tau vs D2–18 P301L tau, p = 0.0004). We
Figure 8. P301L tau increases the association with PP1g isoform in primary hippocampal neurons. A, PLA experiments were repeated with the Tau7 antibody and a PP1g -specific antibody
verified with immunoblot. Recombinant PP1 isoforms were probed with a PP1g antibody (green) and a 6xHis antibody (red). B, PLA puncta were quantified and normalized to area of Tau12
staining (i.e., exogenous tau staining). P301L tau (28.06 7.0 puncta/nm2) expression increased levels of PLA signal compared with WT tau (11.36 1.9 puncta/nm2), whereas R5L (16.26
2.1 puncta/nm2) expression did not significantly change. Data represent mean6 SD of three replicates and were analyzed using a repeated measures one-way ANOVA and Tukey’s post hoc
multiple comparison test; *p  0.05. C, A Tau7 primary antibody deletion demonstrated the lack of background signal when PLA is performed with the PP1g antibody only. D–F,
Associations between WT tau and endogenous rat PP1g (PLA, green puncta; Tau12, red) were identified in the neuronal processes (E) and cell bodies (F) of the neurons. G–I, Lentiviral expres-
sion of P301L tau increased PLA puncta, which were found in processes (H) and cell bodies of neurons (I). J–L, PLA in the presence of R5L tau also demonstrated an association between tau
and PP1g , localized to the processes (K) and cell bodies (L) of the neurons. M–O, PLA was performed in untransduced neurons to identify an association between endogenous rat tau and
PP1g , also found in neuronal processes (N) and cell bodies (O). Scale bars: 20mm for all images.
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observed a similar effect on pause frequency in the anterograde
direction whereby PAD deletion rescued the P301L-induced
increases (Fig. 10D; F(3,16) = 7.150, p = 0.0029; WT tau vs P301L
tau, p = 0.0281; WT tau vs D2–18 P301L tau, p = 0.8536; P301L
tau vs D2–18 P301L tau, p = 0.0056). We did not detect significant
increases in retrograde pause frequency in this experiment (Fig.
10E; F(3,16) = 3.080, p = 0.0574; WT tau vs P301L tau, p = 0.1963)
but deletion of amino acids 2–18 in P301L tau significantly
reduced pause frequency compared with full-length P301L tau
expression (p = 0.0479). This indicates that alterations in FAT eli-
cited by P301L are PAD dependent, as previously shown for other
pathogenic forms of tau in the isolated squid axoplasm model
(Kanaan et al., 2011).
Discussion
Impairments in FAT are widely regarded as a major pathogenic
event contributing to dying-back degeneration of neurons in AD
and related tauopathies and are linked to pathogenic tau forms
(Kneynsberg et al., 2017). Transgenic P301L tau mice, for exam-
ple, recapitulate many aspects of tau toxicity including axonal
degeneration (Lewis et al., 2000; Ludvigson et al., 2011; de
Calignon et al., 2012). These studies also documented FAT
impairments (Bertrand et al., 2013) before overt degeneration
(Gilley et al., 2012; Majid et al., 2014) but did not examine under-
lying molecular mechanisms. Using two tau mutations that cause
inherited tauopathies we provide novel mechanistic insights into
how tau impairs FAT.
Tau-induced FAT impairments in the isolated squid axo-
plasm model are PAD dependent, and pharmacological PP1
inhibitors rescue the effects in this model system (LaPointe et al.,
2009; Kanaan et al., 2011). This led us to examine whether FTLD
mutant tau inhibited FAT in squid axoplasms and in mammalian
hippocampal neurons and to identify specific PP1 isoforms
mediating the potential toxic effect. Unlike most other patho-
genic tau forms that impair anterograde FAT, P301L and R5L
tau disrupted both anterograde and retrograde FAT in the squid
axoplasm and primary rat hippocampal neurons. Based on our
findings, the bulk of this disruption occurred through a specific
PAD- and PP1g -dependent mechanism. The negative impact on
retrograde FAT is similar to that of phosphomimics at select sites
Figure 9. Tau-induced increases in active PP1 is dependent on PAD. PAD, a conformationally displayed biologically active motif in the extreme amino terminus of tau, was deleted in WT and
P301L tau by removing amino acids 2–18 (D2–18). A, B, The full-length and D2–18 constructs were expressed in HEK293 cells, in addition to PP1a, at similar levels (B; WT tau, 4.026 0.54;
D2–18 WT, 3.246 0.63; P301L, 5.326 1.52; D2–18 P301L, 4.046 0.58). C, Levels of active PP1a (as indicated by changes in inactive pT320 PP1) were identified using a phospho-Thr320 PP1
antibody (red), and total levels were detected using an anti-HaloTag antibody (green). D, Deletion of PAD resulted in significantly lower levels of active PP1 compared with expression of full-length
tau in both WT and P301L backgrounds (WT tau, 0.34096 0.0366; D2–18 WT, 0.42326 0.0336; P301L, 0.21476 0.0507; D2–18 P301L, 0.40626 0.0406). E, F, WT tau, D2–18 WT, P301L,
and D2–18 P301L were expressed at similar levels (F) along with PP1b (WT tau, 1.716 0.14; D2–18 WT, 1.646 0.28; P301L, 1.686 0.24; D2–18 P301L, 1.786 0.41). G, Immunoblotting
of total PP1 (green) and inactive PP1b (red, pT320 PP1 antibody corresponds to pT316 in PP1b ). H, Active PP1b levels decreased in the presence of D2–18 WT and D2–18 P301L compared
with full-length WT and P301L tau (WT tau, 0.0393 6 0.0067; D2–18 WT, 0.1525 6 0.0281; P301L, 0.0162 6 0.0062; D2–18 P301L, 0.1231 6 0.0125). I, WT tau, D2–18 WT, P301L, and
D2–18 P301L in cells coexpressing PP1g . J, Quantification indicated similar levels of tau expression with all constructs (WT tau, 8.826 1.27; D2–18 WT, 7.266 1.57; P301L, 8.326 2.32; D2–
18 P301L, 6.966 1.73). K, Immunoblots of total PP1 (green) and inactive PP1g (red, pT320 PP1 antibody corresponds to pT311 in PP1g ). L, The D2–18 WT resulted in decreased levels of active
PP1g compared with full-length counterparts (WT tau, 0.05786 0.0099; D2–18 WT, 0.14286 0.0154; P301L, 0.01016 0.0022; D2–18 P301L, 0.08626 0.0471). P301L tau expression led to
higher levels of active PP1 compared with WT tau, and this effect was reduced about ninefold on PAD deletion in D2–18 P301L. Tau signal was normalized to GAPDH loading control (B, F, J) and
pT320 PP1 signal was normalized to total PP1 signal (D, H, L). Data in legend are reported in ratios of the signal intensities in arbitrary units. All data in figure are mean6 SD and were compared
using repeated measures one-way ANOVAs with a Geisser–Greenhouse correction and Tukey’s post hoc multiple comparison test, *p 0.05).
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in tau (e.g., S422, S199, and S202), which we previously tested in
isolated squid axoplasm (Tiernan et al., 2016; Morris et al.,
2020), suggesting that some pathogenic tau forms may also dis-
rupt pathways involved in the regulation of retrograde FAT and
cellular processes dependent on this direction of transport (e.g.,
neurotrophic factor signaling).
We detected FAT dysfunction through distinct readouts in
the two assays. Because of the unique method of microscopy
used to evaluate FAT in isolated axoplasm, effector proteins that
promote kinesin release from either cargo (Morfini et al., 2004)
or microtubules (Morfini et al., 2009, 2013) promote a reduction
in FAT rate readout (Song et al., 2016). In primary neuron cul-
tures, fluorescence-based confocal microscopic analysis of FAT
allows separate evaluation of translocation rates from pauses.
Our findings align with others showing that P301L tau does not
impair FAT instantaneous velocity. For example, there was no
apparent deficit in mitochondrial transport velocity in primary
neurons or tibial nerve explants from P301L knock-in mice
(pauses were not assessed; Gilley et al., 2012; Rodríguez-Martín
et al., 2016). Collectively, the data reported here and previously
indicate that pathologic forms of tau that cause disease in
humans can significantly disrupt FAT in neurons.
PP1 involvement in tau-mediated FAT dysfunction is sup-
ported by multiple protein–protein interaction assays showing
P301L tau robustly increased interaction with PP1. PP1 has more
than 200 binding partners that modulate localization of PP1, en-
zymatic activity, degradation, and/or substrate recognition either
directly or by preventing interaction with other regulators
(Bollen et al., 2010; Peti et al., 2013), and the roles of individual
PP1 isoforms are incompletely understood (Heroes et al., 2013).
The only prior study addressing tau–PP1 interactions found that
tau localized PP1 to microtubules (Liao et al., 1998). Several
questions remained unanswered, including the specific PP1 iso-
forms involved and functional consequences of the interactions.
Together, our work and that from Liao et al. (1998) demonstrate
that tau interacts with and activates PP1, consistent with our
working hypothesis that tau regulates signaling pathways involved
in numerous cellular processes, including those involved in FAT
modulation (Mueller et al., 2021).
Like tau, several known PP1-interacting partners contain low
complexity domains, which are thought to impart flexibility and
allow simultaneous interaction with multiple binding motifs in
PP1 (Mukrasch et al., 2009; Marsh et al., 2010; Ragusa et al.,
2010; Choy et al., 2012). The P301L mutation is located within
the microtubule binding domain (MTBR) of tau and changes the
301PGGGmotif immediately preceding the 306VQIVYK sequence
involved in tau aggregation. Relatively little is known about spe-
cific global conformational effects elicited by the P301L muta-
tion, but it seems to open conformation of tau in a microtubule-
bound state while also reducing microtubule-binding affinity
(Hasegawa et al., 1998; Dayanandan et al., 1999; Di Primio et al.,
2017). Such conformation could expose the N-terminal PAD or
theMTBRs to facilitate tau–PP1 binding and subsequent changes
to PP1 activity. In contrast, the R5L mutation (within PAD) did
lead to increased active PP1 levels without altering binding to
PP1. These data suggest a potential two-component process by
which tau acts as a scaffold protein, with the MTBR mediating
the interaction between tau and PP1, whereas PAD is more
directly involved in modulating PP1 activation. Supporting this,
PAD deletion reduced levels of active PP1 in WT and P301L
backgrounds and rescued P301L-dependent FAT effects in neu-
rons, aligning with previous results from squid axoplasms
(LaPointe et al., 2009; Kanaan et al., 2011). The specific impact of
Figure 10. PAD deletion rescues P301L tau-induced increases in pause frequency.
Transport of fluorescent synaptophysin was analyzed in the presence of full-length and PAD
deletion (D2–18) WT and P301L tau constructs. A, Anterograde segment velocity was not
significantly altered (WT tau, 2.05 6 0.24mm/s; D2–18 WT, 2.03 6 0.16mm/s; P301L,
2.18 6 0.31mm/s; D2–18 P301L, 1.76 6 0.26mm/s). B, No significant changes were
detected in retrograde segment velocity (WT tau, 2.05 6 0.24mm/s; D2–18 WT, 2.06 6
0.24mm/s; P301L, 2.036 0.16mm/s; D2–18 P301L, 1.966 0.22mm/s). C, The P301L tau
induced a significant increase in total pause frequency compared with WT tau that was res-
cued by PAD deletion, whereas deletion of PAD in WT tau did not alter pause frequency (WT
tau, 0.2158 6 0.0375 pauses/s; D2–18 WT, 0.1951 6 0.0363 pauses/s; P301L, 0.3980 6
0.0723 pauses/s; D2–18 P301L, 0.2018 6 0.0772 pauses/s). D, The directionality of these
effects was determined by separating pauses into the anterograde and retrograde directions.
P301L again induced an increase in anterograde pause frequency that was rescued by PAD
deletion in D2–18 P301L (WT tau, 0.1623 6 0.0348 pauses/s; D2–18 WT, 0.1358 6
0.0431 pauses/s; P301L, 0.2618 6 0.0629 pauses/s; D2–18 P301L, 0.1370 6 0.0540
pauses/s). E, A significant change in retrograde pause frequency was not observed between
WT tau and P301L tau. However, retrograde pause frequency with D2–18 P301L expression
was significantly reduced compared with full-length P301L (WT tau, 0.1614 6 0.0274
pauses/s; D2–18 WT, 0.1601 6 0.0105 pauses/s; P301L, 0.2142 6 0.0502 pauses/s; D2–
18 P301L, 0.14156 0.05,443 pauses/s). Data were compared using a one-way ANOVA with
Tukey’s multiple comparison test, and each data point represents an independent replicate
(n = 5; the data are mean6 SD; *p  0.05).
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the R5L mutation on tau conformation is unknown, but it could
induce alterations similar to other mutations that increase PAD
exposure (Kanaan et al., 2011; Combs et al., 2016). Continued
investigations into how specific tau regions functionally interact
with various PP1 binding motifs and the basis for the specificity
of interactions with PP1 isoforms are warranted.
PP1a, PP1b , and PP1g are the main catalytic isoforms in
brain and differ somewhat in expression, localization, and speci-
ficity for binding partners and substrates. Each PP1 isoform is
found in mammalian axons and axon terminals, presumably in
the appropriate position to regulate cargo delivery (Strack et al.,
1999; Bordelon et al., 2005). PLA signal localized to neuronal
projections, but additional experiments are needed to definitively
identify subcellular differences. In the in vitro assays, we estab-
lished that tau interacted similarly with PP1a and PP1g , whereas
much less interaction occurred with PP1b . PP1a and PP1g
share some regions with higher sequence homology than corre-
sponding regions in PP1b (Scotto-Lavino et al., 2010). Some pro-
teins, like neurabins, also interact with PP1a/g but weakly with
PP1b , helping localize PP1 to synapses and altering activity (Terry-
Lorenzo et al., 2002). This specificity depends on multiple domains
surrounding canonical PP1-binding sequences (Carmody et al.,
2004), reinforcing the complexity of PP1 regulatory interactions.
The agreement among our results in these assays, the neuronal PLA
experiments, and those by Liao et al. (1998) using brain-purified
microtubule fractions provides confidence that a tau–PP1 interac-
tion is biologically relevant. Although mutant tau interacted simi-
larly with PP1a or PP1g in non-neuronal assays, our findings in
mammalian neurons suggest that the tau–PP1g interaction is spe-
cifically responsible for the main effects on FAT in hippocampal
neurons. In vivo, the molecular basis of PP1 isoform-specific effects
in neurons likely involves differences in subcellular localization or
cell-type-specific expression of selected PP1 isoforms, as well as the
binding partners.
Although tau is a known substrate for PP1 (Liu et al., 2005;
Rahman et al., 2005) this does not preclude a PP1-regulatory
function, and several other PP1-regulating proteins serve this
dual role (Bollen et al., 2010). Direct regulation of neuronal PP1
activity also occurs through an inhibitory Cdk5-mediated phos-
phorylation at a C-terminal threonine residue (T320/T316/T311
in PP1a/b /g , respectively) that is rapidly autodephosphorylated
by active PP1 (Dohadwala et al., 1994; Hou et al., 2013), thus
providing a good inverse marker for the pool of active PP1 in
cells. We previously showed Cdk5 inhibition also reduces FAT
through activation of the PP1/GSK3b pathway (Morfini et al.,
2004). Here, we provided evidence that tau expression increased
levels of active PP1 in cultured cells. Our studies cannot rule out
the possibility that yet unidentified additional PP1 or tau-binding
partners are involved in this regulatory function. In our model
GSK3 is activated on dephosphorylation by PP1 and responsible
for phosphorylating kinesin light chain, inducing cargo release,
though additional studies are needed to characterize the interac-
tion of GSK3 with tau. Likely because of its multifunctional role
in various cellular processes, GSK3b knockdown via shRNA
was too disruptive to FAT to be useful in this context (data not
shown).
Collectively, these experiments describe a specific PP1g -de-
pendent molecular mechanism by which P301L and R5L tau
promote FAT impairments in mammalian neurons by increasing
levels of active PP1. Collectively, the available data highlight a
mechanism where different tau mutations similarly elicit toxic
effects on FAT. Specifically, the P301L mutation in the MTBR
increases PP1 binding and subsequently increases active PP1,
whereas the R5L mutation in PAD enhances active PP1 without
increased binding of PP1 relative to WT tau. Both mutations dis-
rupt FAT in hippocampal neurons, evidenced by increased cargo
pausing, an event that is PAD dependent and specifically medi-
ated by PP1g . This, and several other studies, now support our
working model in which pathologic tau modifications (i.e.,
aggregation, abnormal phosphorylation, and FTLD mutations)
alter PP1g function resulting in dysregulation of FAT (Kanaan
et al., 2013; Brady and Morfini, 2017). Given the large number of
substrates targeted by PP1 isoforms, aberrant substrate activation
may induce toxicity by disrupting the homeostasis of signaling
pathways involved in the regulation of FAT and other cellular
processes in tauopathies.
References
Berry RW, Sweet AP, Clark FA, Lagalwar S, Lapin BR, Wang T, Topgi S,
Guillozet-Bongaarts AL, Cochran EJ, Bigio EH, Binder LI (2004) Tau epi-
tope display in progressive supranuclear palsy and corticobasal degenera-
tion. J Neurocytol 33:287–295.
Bertrand A, Khan U, Hoang DM, Novikov DS, Krishnamurthy P,
Rajamohamed Sait HB, Little BW, Sigurdsson EM, Wadghiri YZ (2013)
Non-invasive, in vivo monitoring of neuronal transport impairment in a
mouse model of tauopathy using MEMRI. Neuroimage 64:693–702.
Binder LI, Frankfurter A, Rebhun LI (1985) The distribution of tau in the
mammalian central nervous system. J Cell Biol 101:1371–1378.
Bollen M, Peti W, Ragusa MJ, Beullens M (2010) The extended PP1 toolkit:
designed to create specificity. Trends Biochem Sci 35:450–458.
Bordelon JR, Smith Y, Nairn AC, Colbran RJ, Greengard P, Muly EC (2005)
Differential localization of protein phosphatase-1alpha, beta and gamma1
isoforms in primate prefrontal cortex. Cereb Cortex 15:1928–1937.
Brady ST, Morfini GA (2017) Regulation of motor proteins, axonal transport
deficits and adult-onset neurodegenerative diseases. Neurobiol Dis
105:273–282.
Brady ST, Richards BW, Leopold PL (1993) Assay of vesicle motility in squid
axoplasm. Methods Cell Biol 39:191–202.
Caccamo D, Katsetos CD, Herman MM, Frankfurter A, Collins VP,
Rubinstein LJ (1989) Immunohistochemistry of a spontaneous murine
ovarian teratoma with neuroepithelial differentiation. Neuron-associated
beta-tubulin as a marker for primitive neuroepithelium. Lab Invest
60:390–398.
Carmel G, Mager EM, Binder LI, Kuret J (1996) The structural basis of
monoclonal antibody Alz50’s selectivity for Alzheimer’s disease pathol-
ogy. J Biol Chem 271:32789–32795.
Carmody LC, Bauman PA, Bass MA, Mavila N, DePaoli-Roach AA, Colbran
RJ (2004) A protein phosphatase-1gamma1 isoform selectivity determi-
nant in dendritic spine-associated neurabin. J Biol Chem 279:21714–
21723.
Choy MS, Page R, Peti W (2012) Regulation of protein phosphatase 1 by
intrinsically disordered proteins. Biochem Soc Trans 40:969–974.
Coleman JE, Huentelman MJ, Kasparov S, Metcalfe BL, Paton JF, Katovich
MJ, Semple-Rowland SL, Raizada MK (2003) Efficient large-scale pro-
duction and concentration of HIV-1-based lentiviral vectors for use in
vivo. Physiol Genomics 12:221–228.
Combs B, Kanaan NM (2017) Exposure of the amino terminus of tau is a
pathological event in multiple tauopathies. Am J Pathol 187:1222–1229.
Combs B, Hamel C, Kanaan NM (2016) Pathological conformations involv-
ing the amino terminus of tau occur early in Alzheimer’s disease and
are differentially detected by monoclonal antibodies. Neurobiol Dis
94:18–31.
Combs B, Tiernan CT, Hamel C, Kanaan NM (2017) Production of recombi-
nant tau oligomers in vitro. Methods Cell Biol 141:45–64.
Cox K, Combs B, Abdelmesih B, Morfini G, Brady ST, Kanaan NM (2016)
Analysis of isoform-specific tau aggregates suggests a common toxic
mechanism involving similar pathological conformations and axonal
transport inhibition. Neurobiol Aging 47:113–126.
da Cruz e Silva EF, Fox CA, Ouimet CC, Gustafson E, Watson SJ, Greengard
P (1995) Differential expression of protein phosphatase 1 isoforms in
mammalian brain. J Neurosci 15:3375–3389.
Dayanandan R, Van Slegtenhorst M, Mack TG, Ko L, Yen SH, Leroy K,
Brion JP, Anderton BH, Hutton M, Lovestone S (1999) Mutations in tau
Combs et al. · FTLD-Tau and PP1 Impair Axonal Transport J. Neurosci., November 10, 2021 • 41(45):9431–9451 • 9449
reduce its microtubule binding properties in intact cells and affect its
phosphorylation. FEBS Lett 446:228–232.
de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH,
Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones
TL, Hyman BT (2012) Propagation of tau pathology in a model of early
Alzheimer’s disease. Neuron 73:685–697.
Di Primio C, Quercioli V, Siano G, Rovere M, Kovacech B, Novak M,
Cattaneo A (2017) The distance between N and C termini of tau and of
FTDP-17 mutants is modulated by microtubule interactions in living
cells. Front Mol Neurosci 10:210.
Dohadwala M, da Cruz e Silva EF, Hall FL, Williams RT, Carbonaro-Hall
DA, Nairn AC, Greengard P, Berndt N (1994) Phosphorylation and inac-
tivation of protein phosphatase 1 by cyclin-dependent kinases. Proc Natl
Acad Sci U S A 91:6408–6412.
Forrest SL, Kril JJ, Stevens CH, Kwok JB, Hallupp M, Kim WS, Huang Y,
McGinley CV, Werka H, Kiernan MC, Götz J, Spillantini MG, Hodges
JR, Ittner LM, Halliday GM (2018) Retiring the term FTDP-17 as MAPT
mutations are genetic forms of sporadic frontotemporal tauopathies.
Brain 141:521–534.
Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M
(2015) Invited review: frontotemporal dementia caused by microtubule-
associated protein tau gene (MAPT) mutations: a chameleon for neuro-
pathology and neuroimaging. Neuropathol Appl Neurobiol 41:24–46.
Gilley J, Seereeram A, Ando K, Mosely S, Andrews S, Kerschensteiner M,
Misgeld T, Brion JP, Anderton B, Hanger DP, Coleman MP (2012) Age-
dependent axonal transport and locomotor changes and tau hypophos-
phorylation in a “P301L” tau knockin mouse. Neurobiol Aging 33:621.
e1–621.e15.
Grabinski TM, Kneynsberg A, Manfredsson FP, Kanaan NM (2015) A
method for combining RNAscope in situ hybridization with immunohis-
tochemistry in thick free-floating brain sections and primary neuronal
cultures. PLoS One 10:e0120120.
Guo T, Noble W, Hanger DP (2017) Roles of tau protein in health and dis-
ease. Acta Neuropathol 133:665–704.
Hasegawa M, Smith MJ, Goedert M (1998) Tau proteins with FTDP-17
mutations have a reduced ability to promote microtubule assembly. FEBS
Lett 437:207–210.
Hedstrom KL, Ogawa Y, Rasband MN (2008) AnkyrinG is required for
maintenance of the axon initial segment and neuronal polarity. J Cell Biol
183:635–640.
Heroes E, Lesage B, Görnemann J, Beullens M, Van Meervelt L, Bollen M
(2013) The PP1 binding code: a molecular-lego strategy that governs
specificity. FEBS J 280:584–595.
Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll
CA, Weintraub ST, Bennett DA, Cryns VL, Berry RW, Binder LI (2004)
Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer’s
disease. J Neurosci 24:7895–7902.
Horowitz PM, Lapointe N, Guillozet-Bongaarts AL, Berry RW, Binder LI
(2006) N-terminal fragments of tau inhibit full-length tau polymerization
in vitro. Biochemistry 45:12859–12866.
Hou H, Sun L, Siddoway BA, Petralia RS, Yang H, Gu H, Nairn AC, Xia H
(2013) Synaptic NMDA receptor stimulation activates PP1 by inhibiting
its phosphorylation by Cdk5. J Cell Biol 203:521–535.
Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-
Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J,
Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E,
Wauters E, van Baren J, et al (1998) Association of missense and 5’-
splice-site mutations in tau with the inherited dementia FTDP-17.
Nature 393:702–705.
Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H,
Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman
E, Götz J (2010) Dendritic function of tau mediates amyloid-beta toxicity
in Alzheimer’s disease mouse models. Cell 142:387–397.
Kanaan NM, Grabinski T (2021) Neuronal and glial distribution of tau pro-
tein in the adult rat and monkey. Front Mol Neurosci 14:607303.
Kanaan NM, Morfini GA, LaPointe NE, Pigino GF, Patterson KR, Song Y,
Andreadis A, Fu Y, Brady ST, Binder LI (2011) Pathogenic forms of tau
inhibit kinesin-dependent axonal transport through a mechanism involv-
ing activation of axonal phosphotransferases. J Neurosci 31:9858–9868.
Kanaan NM, Morfini G, Pigino G, LaPointe NE, Andreadis A, Song Y,
Leitman E, Binder LI, Brady ST (2012) Phosphorylation in the amino
terminus of tau prevents inhibition of anterograde axonal transport.
Neurobiol Aging 33:826.e815–e30.
Kanaan NM, Pigino GF, Brady ST, Lazarov O, Binder LI, Morfini GA (2013)
Axonal degeneration in Alzheimer’s disease: when signaling abnormal-
ities meet the axonal transport system. Exp Neurol 246:44–53.
Kneynsberg A, Combs B, Christensen K, Morfini G, Kanaan NM (2017)
Axonal degeneration in tauopathies: disease relevance and underlying
mechanisms. Front Neurosci 11:572.
Kovacs GG (2015) Invited review: neuropathology of tauopathies: principles
and practice. Neuropathol Appl Neurobiol 41:3–23.
LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI,
Brady ST (2009) The amino terminus of tau inhibits kinesin-dependent
axonal transport: implications for filament toxicity. J Neurosci Res
87:440–451.
Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G (1998) Tau inter-
acts with src-family non-receptor tyrosine kinases. J Cell Sci 111:3167–
3177.
Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van
Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff
K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton
M (2000) Neurofibrillary tangles, amyotrophy and progressive motor dis-
turbance in mice expressing mutant (P301L) tau protein. Nat Genet
25:402–405.
Liao H, Li Y, Brautigan DL, Gundersen GG (1998) Protein phosphatase 1 is
targeted to microtubules by the microtubule-associated protein tau. J Biol
Chem 273:21901–21908.
Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2005) Contributions of protein
phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phos-
phorylation. Eur J Neurosci 22:1942–1950.
LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, Binder LI (1995)
Functional implications for the microtubule-associated protein tau: local-
ization in oligodendrocytes. Proc Natl Acad Sci U S A 92:10369–10373.
Ludvigson AE, Luebke JI, Lewis J, Peters A (2011) Structural abnormalities in
the cortex of the rTg4510 mouse model of tauopathy: a light and electron
microscopy study. Brain Struct Funct 216:31–42.
Machleidt T, Woodroofe CC, Schwinn MK, Méndez J, Robers MB,
Zimmerman K, Otto P, Daniels DL, Kirkland TA, Wood KV (2015)
NanoBRET–A Novel BRET Platform for the Analysis of Protein-Protein
Interactions. ACS Chem Biol 10:1797–1804.
Majid T, Ali YO, Venkitaramani DV, Jang MK, Lu HC, Pautler RG (2014) In
vivo axonal transport deficits in a mouse model of fronto-temporal de-
mentia. NeuroImage Clin 4:711–717.
Marsh JA, Dancheck B, Ragusa MJ, Allaire M, Forman-Kay JD, Peti W
(2010) Structural diversity in free and bound states of intrinsically disor-
dered protein phosphatase 1 regulators. Structure 18:1094–1103.
Mercier JF, Salahpour A, Angers S, Breit A, Bouvier M (2002) Quantitative
assessment of beta 1- and beta 2-adrenergic receptor homo- and hetero-
dimerization by bioluminescence resonance energy transfer. J Biol Chem
277:44925–44931.
Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST (2002) Glycogen syn-
thase kinase 3 phosphorylates kinesin light chains and negatively regu-
lates kinesin-based motility. EMBO J 21:281–293.
Morfini G, Szebenyi G, Brown H, Pant HC, Pigino G, DeBoer S, Beffert U,
Brady ST (2004) A novel CDK5-dependent pathway for regulating GSK3
activity and kinesin-driven motility in neurons. EMBO J 23:2235–2245.
Morfini G, Pigino G, Mizuno N, Kikkawa M, Brady ST (2007) Tau binding
to microtubules does not directly affect microtubule-based vesicle motil-
ity. J Neurosci Res 85:2620–2630.
Morfini GA, You YM, Pollema SL, Kaminska A, Liu K, Yoshioka K,
Björkblom B, Coffey ET, Bagnato C, Han D, Huang CF, Banker G,
Pigino G, Brady ST (2009) Pathogenic huntingtin inhibits fast axonal
transport by activating JNK3 and phosphorylating kinesin. Nat Neurosci
12:864–871.
Morfini GA, Bosco DA, Brown H, Gatto R, Kaminska A, Song Y, Molla L,
Baker L, Marangoni MN, Berth S, Tavassoli E, Bagnato C, Tiwari A,
Hayward LJ, Pigino GF, Watterson DM, Huang CF, Banker G, Brown
RH Jr, Brady ST (2013) Inhibition of fast axonal transport by pathogenic
SOD1 involves activation of p38 MAP kinase. PLoS One 8:e65235.
Morris SL, Tsai MY, Aloe S, Bechberger K, König S, Morfini G, Brady ST
(2020) Defined tau phosphospecies differentially inhibit fast axonal trans-
port through activation of two independent signaling pathways. Front
Mol Neurosci 13:610037.
9450 • J. Neurosci., November 10, 2021 • 41(45):9431–9451 Combs et al. · FTLD-Tau and PP1 Impair Axonal Transport
Mueller RL, Combs B, Alhadidy MM, Brady ST, Morfini GA, Kanaan NM
(2021) Tau: a signaling hub protein. Front Mol Neurosci 14:647054.
Mukrasch MD, Bibow S, Korukottu J, Jeganathan S, Biernat J, Griesinger C,
Mandelkow E, Zweckstetter M (2009) Structural polymorphism of 441-
residue tau at single residue resolution. PLoS Biol 7:e34.
Neumann S, Chassefeyre R, Campbell GE, Encalada SE (2017)
KymoAnalyzer: a software tool for the quantitative analysis of intracellu-
lar transport in neurons. Traffic 18:71–88.
Patterson KR, Ward SM, Combs B, Voss K, Kanaan NM, Morfini G, Brady
ST, Gamblin TC, Binder LI (2011) Heat shock protein 70 prevents both
tau aggregation and the inhibitory effects of preexisting tau aggregates on
fast axonal transport. Biochemistry 50:10300–10310.
Peti W, Nairn AC, Page R (2013) Structural basis for protein phosphatase 1
regulation and specificity. FEBS J 280:596–611.
Poorkaj P, Muma NA, Zhukareva V, Cochran EJ, Shannon KM, Hurtig H,
Koller WC, Bird TD, Trojanowski JQ, Lee VM, Schellenberg GD (2002)
An R5L tau mutation in a subject with a progressive supranuclear palsy
phenotype. Ann Neurol 52:511–516.
Ragusa MJ, Dancheck B, Critton DA, Nairn AC, Page R, Peti W (2010)
Spinophilin directs protein phosphatase 1 specificity by blocking sub-
strate binding sites. Nat Struct Mol Biol 17:459–464.
Rahman A, Grundke-Iqbal I, Iqbal K (2005) Phosphothreonine-212 of
Alzheimer abnormally hyperphosphorylated tau is a preferred substrate
of protein phosphatase-1. Neurochem Res 30:277–287.
Rodríguez-Martín T, Pooler AM, Lau DHW, Mórotz GM, De Vos KJ, Gilley
J, Coleman MP, Hanger DP (2016) Reduced number of axonal mito-
chondria and tau hypophosphorylation in mouse P301L tau knockin
neurons. Neurobiol Dis 85:1–10.
Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M,
Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M,
Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe
KH (2005) Tau suppression in a neurodegenerative mouse model
improves memory function. Science 309:476–481.
Scotto-Lavino E, Garcia-Diaz M, Du G, Frohman MA (2010) Basis for the
isoform-specific interaction of myosin phosphatase subunits protein
phosphatase 1c beta and myosin phosphatase targeting subunit 1. J Biol
Chem 285:6419–6424.
Song Y, Kang M, Morfini G, Brady ST (2016) Fast axonal transport in iso-
lated axoplasm from the squid giant axon. Methods Cell Biol 131:331–
348.
Strack S, Kini S, Ebner FF, Wadzinski BE, Colbran RJ (1999) Differential cel-
lular and subcellular localization of protein phosphatase 1 isoforms in
brain. J Comp Neurol 413:373–384.
Tatebayashi Y, Miyasaka T, Chui DH, Akagi T, Mishima K, Iwasaki K,
Fujiwara M, Tanemura K, Murayama M, Ishiguro K, Planel E, Sato S,
Hashikawa T, Takashima A (2002) Tau filament formation and associa-
tive memory deficit in aged mice expressing mutant (R406W) human
tau. Proc Natl Acad Sci U S A 99:13896–13901.
Terry-Lorenzo RT, Carmody LC, Voltz JW, Connor JH, Li S, Smith FD,
Milgram SL, Colbran RJ, Shenolikar S (2002) The neuronal actin-binding
proteins, neurabin I and neurabin II, recruit specific isoforms of protein
phosphatase-1 catalytic subunits. J Biol Chem 277:27716–27724.
Tiernan CT, Combs B, Cox K, Morfini G, Brady ST, Counts SE, Kanaan NM
(2016) Pseudophosphorylation of tau at S422 enhances SDS-stable dimer
formation and impairs both anterograde and retrograde fast axonal trans-
port. Exp Neurol 283:318–329.
Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein
factor essential for microtubule assembly. Proc Natl Acad Sci U S A
72:1858–1862.
Combs et al. · FTLD-Tau and PP1 Impair Axonal Transport J. Neurosci., November 10, 2021 • 41(45):9431–9451 • 9451
